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Abstract
Rheumatoid arthritis (RA) is a chronic debilitating disease characterized by pro-
gressive joint damage, reduced quality of life, loss of productivity and premature death.
It affects 1% of the adult US population, and is one of the most demanding diseases on
our healthcare resources. Biologic disease modifiers are new drugs that provide hope to
improve the course of RA; however, biologics are among the most expensive specialty
drugs. Although the treatment costs of RA have recently increased with the introduc-
tion of biologics, most of the economic and societal impacts are due to consequences of
RA rather than direct treatment costs. Thus, the cost-effectiveness of biologics in RA
is of high priority as recognized by many agencies including the National Institute of
Health.
This thesis focuses on three limitations of the current cost-effectiveness analyses
(CEA) of biologics in RA. First, Most CEAs are based on randomized clinical trials
(RCT) that are rarely applicable to real-life clinical practice. This thesis examines the
long-term comparative clinical- and cost-effectiveness of biologics using clinical prac-
tice data from a large registry of RA patients (The National Data-Bank of Rheumatic
Diseases). Second, we lack a meta-analytical approach specific to CEAs, and previous
tools are deemed inappropriate. This thesis presents a novel approach of meta-analysis
specific to CEAs. Using this tool we examine if prior CEAs of biologics in RA are
consistent. Third, due to the biologics’ high costs, RA treatment guidelines often rec-
ommend biologics as second line agents after nonbiologics. However, early aggressive
treatment is crucial to avoid permanent joint damage. In this thesis we use Markov
decision processes (MDP) as an innovative approach to identify the optimal timing of
biologics in RA.
iii
The results from this analysis have significant policy, clinical and methodological
implications. This work provides important insights into the comparative effectiveness
of biologics in RA from a US societal perspective, which can influence health policy and
medical insurance coverage decisions. Methodologically, the proposed meta-analytical
approach can be applied to other conditions, and have the potential to reconcile the
inconsistencies in published CEAs and improve the quality of future studies.
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Chapter 1
Introduction
Rheumatoid arthritis (RA) is a chronic debilitating disease affecting 1% of the adult
US population. RA manifestation may vary, but it generally affects the synovial mem-
brane of joints and causes progressive pain, swelling, lower quality of life, disability and
premature death.
RA is one of the most demanding diseases on our healthcare resources. This disease
may significantly lower the productivity of the patients and their caregivers. As a result,
the economic impact of RA on society is estimated to approach that of coronary heart
disease.[1] Although the treatment costs of RA have recently increased dramatically,
the indirect cost (e.g., due to productivity loss) is estimated to be two to three times
higher than the direct treatment costs. Therefore, most of the economic impact of RA
is expected to be due to consequences of RA rather than treatment costs.
Diseases-modifying anti-rheumatic drugs (DMARDs) are the mainstay for slow-
ing RA joint damage, improving the prognosis and RA patients and their quality of
life. These drugs are generally categorized into nonbiologic (synthetic) and biolog-
ics DMARDs. Nonbiologic DMARDs include a wide class of synthetic medications
such as methotrexate, sulfasalazine, hydroxychloroquine and corticosteroids. Biologic
DMARDs, such as infliximab, etanercept and adalimumab, are complex compounds that
1
2target the inflammatory mediators involved in RA. Biologics are newer and generally
more effective than nonbiologics. Thus, biologics are an integral part in treating RA pa-
tients. However, biologics are significantly more expensive than nonbiologic DMARDs.
The average annual cost of biologics is about $25,000 per patient compared to a small
fraction of this amount for nonbiologic agents. Cost consideration is an important lim-
iting factor of biologics use, and guidelines often recommend their use after failure of
nonbiologic DMARDs.[2, 3]
This combination of marked benefits and high costs brings a challenging dilemma in
terms of the appropriate allocation of limited healthcare resources. As demand for these
new costly drugs rises, it is important to understand the long-term comparative clinical-
and cost-effectiveness of these agents. The cost-effectiveness of biologics in treating RA
is widely recognized by many agencies, including the National Institute of Health, as a
high priority research area.[4]
Most prior cost-effectiveness analyses (CEAs) that compare biologic to nonbiologic
DMARDs are based on randomized controlled trial (RCT) data.[4] However, most RCTs
are shown to inflate the benefit of biologics compared to clinical practice.[5, 6, 7, 8] Two
important causes for this bias are RCT eligibility and the Hawthorne Effect. To be
eligible to participate in an RCT, RA participants must exceed certain disease activity
thresholds that exclude the majority of biologic eligible patients.[7] One study have
shown that on average, 90% of individuals in two large clinical RA cohorts were not
eligible to participate in biologics RCTs.[9] In addition, another study showed that
RCT-eligible patients are consistently more responsive to biologics than those ineligible
to participate.[7] A third study have shown that half of the improvement observed
during an RCT period disappeared immediately after the trial terminated due to the
Hawthorne effect.[10] Consequently, CEAs that are based on RCTs may favor biologics
compared to what is observed in real-life clinical practice.[8]
3Chapter 2 discusses the cost-effectiveness analysis of biologics in RA from a US
societal perspective using a National Data Bank for Rheumatic Diseases (NDB). This
analysis proposes to narrow the gap between clinical practice and comparative effec-
tiveness evidence by using a large database of real-life RA patients. The NDB consists
of detailed self-reported semiannual questionnaires from 28,960 community RA patients
from around the US.[11]
In Chapter 3, we develop a novel technique of meta-analysis specific to CEAs, we
implement this approach to RCT-based CEAs that compare biologics to nonbiologics,
and we investigate the impact of using NDB parameter estimates on the findings of the
RCT-based CEAs. Prior CEAs of biologics are inconsistent.[4] Studies sponsored by
the pharmaceutical industry often report favorable outcomes.[12] It is unclear if this
inconsistency is due to the parameter values used as inputs, or if these studies are
structurally dissimilar. Traditional meta-analytic approaches used to summarize the
findings from RCTs are deemed inappropriate for CEAs due to the large variation in
the study population and parameter estimates.[13] Thus, our approach provides the first
attempt to conduct meta-analysis on CEA and economic evaluations.
In Chapter 4, we use Markov decision processes (MDP) as an innovative approach
to understand if there is a window of opportunity for biologics in early RA. Specifically,
this chapter investigates the relative cost-effectiveness of biologics in early versus late
RA. MDP is an operational tool that have been successfully utilized in recommending
liver transplant in treating chronic liver diseases and HIV treatment sequences.[14, 15].
MDP is a natural choice for RA treatment strategies due to the chronic nature of this
disease and the frequent change of medications. The practice of early diagnosis and
treatment in the first few months after RA disease process starts is crucial to prevent
permanent joint damage and deformity. Rheumatologists recognize the importance
of this window of opportunity in improving quality of life, reducing work disability,
4and preventing premature death.[16, 17] However, due to cost considerations, guideline
often recommend biologics when remission or low disease activity are not achievable
with nonbiologics.[18, 19, 20, 2, 3] In addition, the pharmaceutical industry presses to
expand biologics utilization and increase their market share to early RA arguing that
the increased benefit through improved quality of life and reduced work disability can
offset the high short-term biologics costs. Nonetheless, our understanding of the optimal
timing of biologics is limited because all CEAs are conducted with traditional tools that
are inappropriate to investigate the best time to initiate biologics. The current analysis
is the first that implements MDP in RA treatment strategies.
In summary, the specific aims of this thesis are to investigate:
1. if biologics are utilized cost-effectively in clinical practice in the US,
2. if using clinical practice effectiveness alters the findings of prior RCT-based CEAs,
and
3. if there exists a window of opportunity during which biologics are most cost-
effective in early RA.
Comparative effectiveness of biologics in RA is recognized as one of the highest
priorities of the National Institute of Health (NIH) in the US. The work conducted
in this thesis has important clinical, policy, and methodological implications. First,
medical insurance coverage can be updated to suggest treatment choices that are best
for RA patients and that can lower societal costs. Second, this analysis can improve
upon the clinical guidelines by incorporating both long-term individual benefits and
societal costs. Third, this thesis addresses health services research issues critical to
priority populations. RA is most prevalent among women and is an important cause
of disability. In addition, this thesis incorporates advanced methodological tools from
operations research into the clinical practice of RA treatment strategies. This thesis
provides the first methodological attempt to conduct meta-analysis specific to CEAs.
5This approach can be easily extended and tested in other conditions and diseases to
reveal sources of inconsistency in prior CEAs, and help improve the quality of future
analyses. In addition, this thesis is the first to utilize MDP to model the sequential
decisions involved in RA treatment strategies over the long-term nature of this disease.
Chapter 2
Are Anti-TNFs Cost-Effective? Analysis
Based on the Real-Life Experience of
Patients with Rheumatoid Arthritis
Background. Previous cost-effectiveness analyses (CEAs) of biologics for patients
with rheumatoid arthritis (RA) based on randomized controlled trials (RCTs) are lim-
ited by their short time horizon and lack of generalizability to real-world effectiveness.
Objective: To conduct a CEA of biologics in real-life RA patients using data from an
observational study.
Methods. We developed a Markov simulation model to estimate quality-adjusted life
years (QALYs) and costs associated with several treatment strategies for RA patients
over the lifespan. We evaluated strategies based on different sequences of 5 biologics
(etanercept, infliximab, adalimumab, abatacept, and rituximab) compared to conven-
tional non-biologic DMARDs. We modeled the discontinuation rate of each biologic as
well as the reason (i.e. serious AE, cost of medication, or ineffectiveness). Those who
discontinued because of ineffectiveness were allowed to transition to the next biologic in
the sequence based on the probability of switching biologics in an observational study
6
7(the National Data Bank [NDB]). Those who discontinued because of the other rea-
sons switched to nonbiologics. Markov health states were defined by Health Assessment
Questionnaire (HAQ) scores and the types of medication the patients received. Tran-
sition probabilities, effectiveness measures (i.e., HAQ score improvements), AE rates,
quality of life weights, and discontinuation rates were estimated from the NDB. Direct
and indirect costs (2009 US dollars) were obtained from the literature. Both costs and
effectiveness are discounted by 3% annually.
Results. In the base-case analysis, biologics were generally more effective than non-
biologics. The most cost-effective sequence of biologics was EtanerceptInfliximabAdali-
mumab (EIA), with an incremental lifetime effectiveness of 0.3 QALYs compared to non-
biologics. The EIA strategy had an incremental lifetime cost of about $170,000 yielding
an ICER of nearly 0.5M/QALY, which is well above willingness to pay (WTP) thresh-
olds considered acceptable. Our findings were robust to one-way sensitivity analyses. In
a series of what-if scenarios, an immediate and sustainable improvement in HAQ, faster
HAQ progressions, and reduced biologics costs lowered ICERs below $100K/QALY.
Conclusion. Using observational data, we were unable to observe the cost-effectiveness
reported by RCT-based CEAs. The primary reasons for this discrepancy relate to a
lower incremental effectiveness of biologics in real-life patients compared to those en-
rolled in RCTs.
82.1 Background
There are several biological therapies available to treat patients with rheumatoid arthri-
tis (RA), all of which are generally more effective than nonbiologic disease-modifying
antirheumatic drugs (DMARDs) but cost $17,800 to $24,900 annually. This combina-
tion of marked benefits and high costs brings a challenging dilemma in terms of the
appropriate allocation of limited resources. As demand for these new costly drugs rises,
it is important to understand the long-term clinical effectiveness and cost-effectiveness
of these agents. Most cost-effectiveness analyses (CEAs) that compare biologic to non-
biologic DMARDs were based on randomized controlled trial (RCT) data.[4] In these
analyses, estimates of RCT efficacy were used directly as clinical effectiveness. How-
ever, trial-based efficacy of biologics has been shown to be significantly greater than
real-life effectiveness.[7, 5, 8] This difference is attributed to RCT eligibility criteria and
the timing of measuring drug effects. Vashisht et al. found that, on average, 90% of
individuals in two large clinical RA cohorts would not have been eligible for any of the
RCTs used for the nine biologics currently approved by the US Food and Drug Admin-
istration (FDA).[9] Furthermore, Kievit et al. showed that RCT-eligible patients have a
44% higher response than RCT-ineligible patients.[7] The timing of receiving biologics
and measuring their effect may introduce additional bias. Specifically, disease activity
observed at RCT baseline may be artificially elevated if participants abstain from their
medications before the trial starts as per protocol.[21, 22, 23] RCT-based CEAs that
ignore this timing effect overestimate the effectiveness of biologics. Accordingly, we
developed a simulation model to conduct a CEA of biologics using effectiveness data
from real-life patients in a large RA registry in the US (the national Data Bank for
Rheumatic Diseases [NDB]), supplemented with data from the medical literature.[11]
92.2 Methods
2.2.1 Model
We developed a microsimulation model to simulate the lifetime experience of one million
hypothetical RA patients similar to those in the NDB (Figure 2.1). The model com-
putes the clinical benefits, measured as gains in quality-adjusted life years (QALYs),
and lifetime costs associated with biologic and nonbiologic treatment strategies. The
comparison strategy of non-biologic DMARDs represents the experience of the average
biologic-nave RA patients as observed in the NDB. We evaluated the outcomes for five
different biologics: etanercept, infliximab, adalimumab, abatacept and rituximab. We
found these five biologics to be the most frequently prescribed in the NDB from 1998
through 2011. In the biologic strategies, we allowed patients to receive a maximum of
three different biologics in a sequence, depending on observed discontinuation rates and
reason for discontinuation. Thus, the resulting number of unique biologic strategies was
60 (five biologics as first choice four biologics as second choice three biologics as the
third choice).
We used the Health Assessment Questionnaire Disability Index (HAQ) to represent
disease severity. HAQ correlates well with patient outcomes such as health-related
quality of life (HRQoL), cost and mortality.[24, 25, 26, 10] In addition, HAQ is a well-
validated instrument and is the most commonly used instrument to define health status
in RA CEAs.[27, 28] Each simulated patient was assigned a baseline age and HAQ,
drawn from a joint distributions that reflect biologic-nave RA patient characteristics in
the NDB at the time they started biologics. Each 6-month cycle, a simulated patient
may experience a change in their HAQ status (i.e., disease progression), which in turn
affects their HRQoL, cost, and disease-specific mortality. In addition, they face a risk
of experiencing an adverse event, depending on the drug they are receiving, as well
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as a risk of discontinuing their current biologic. We considered three possible reasons
for discontinuation as recorded by patients in the NDB: (1) ineffectiveness, (2) serious
adverse event, or (3) high out-of-pocket cost or other personal decision making factors.
If a biologic becomes ineffective, we allowed the patient to switch to the next biologic
in the sequence (to a maximum of three). A 6-month cycle length was chosen to be
consistent with other RA CEA models and because it corresponds well to the suggested
decision points in the American College of Rheumatology (ACR) guidelines.[20]
For each of the 61 strategies we calculated discounted QALYs and discounted lifetime
costs, using a discount rate of 3% per year. To calculate QALYs and lifetime costs, we
assigned a HRQoL weight and cost, respectively, to each 6-month cycle based on a
simulated patients HAQ score and the presence of any adverse events. All statistical
analyses were conducted in Stata (StataCorp. 2011. Stata Statistical Software: Release
12. College Station, TX: StataCorp LP.) and all model development and analyses were
conducted using TreeAge Pro (TreeAge Software, Inc., Williamstown, MA) and Visual
Basic for Applications in Microsoft Excel.
2.2.2 Data
The NDB consists of detailed self-reported semiannual questionnaires from 28,960 com-
munity RA patients from around the US. Details of this databank are described else-
where. [11] All parameters were derived from the NDB when possible; otherwise, they
were derived from the medical literature. We followed three steps to derive our param-
eter estimates. First, we reviewed published NDB studies for existing estimates. For
example, the clinical benefits of biologics were obtained directly from a recent NDB
publication[29] that provides the adjusted annual disability progression rates for nonbi-
ologics and three of the biologics: infliximab, etanercept, and adalimumab. Second, we
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conducted necessary analyses for parameters that were not readily available. For exam-
ple, we repeated the aforementioned published analysis of the NDB to obtain estimates
for abatacept and rituximab. Finally, we conducted a literature search to obtain some
of the cost and HRQoL estimates. Model parameter values are listed in Table 2.1.
2.2.3 Benefits
Treatment effectiveness was modeled through changes in HAQ and the subsequent effect
on HRQoL and mortality. As previously noted, we used published annual progression
rates derived from an analysis of the NDB,[29]and repeated the analysis for biologics not
included in the original study. For example, the annual progression rate for nonbiologic
therapy was 0.018, indicating that on average HAQ increases by 0.018 per year for RA
patients on nonbiologics. The estimated progression rates for biologics were all slower
than that for nonbiologics (see Table 2.1). In the base-case analysis, we assumed no
immediate improvement in the baseline HAQ separate from the progression rates. In
a sensitivity analysis, we tested the effect of immediate improvement in the baseline
HAQ. We modeled mortality as a function of age and HAQ. The age-specific mortality
was derived from the US life tables,[30] and the additional mortality due to RA was
modeled as a function of HAQ score. For example, a patient with a HAQ score of
2 experiences an excess RA-specific death rate of 0.0018 (Table 2.1).[26] We assumed
an additive approach to calculate an overall mortality rate from the age-specific and
RA-specific rates.[31]
2.2.4 Harms
We derived 6-month probabilities of adverse events related to treatment from a pub-
lished systematic review.[32] Adverse events were categorized as serious infection, non-
melanoma skin cancer, and minor side effects. We assumed that all adverse events were
12
short-term in that they were associated with a 6-month decrease in HRQoL, a 6-month
increase in cost, and serious infections were associated with a case fatality rate.[33, 34]
We assumed that all biologics were associated with the same risk of adverse events,
which were higher than the risks for nonbiologic therapy. Although there is evidence
that lymphoma is also associated with biologics,[35, 36] the evidence is weak and we
did not include this adverse event in our base-case analysis. However, we did include
this long-term adverse event and its associated mortality[37] in a sensitivity analysis.
2.2.5 Outcomes
Health-related Quality of Life(HRQoL)
Health outcome was measured in QALYs, which combines HRQoL and life expectancy.
To estimate QALYs we identified HRQoL weights (i.e., utilities) to assign to simulated
patients for every 6-month cycle. Weights of 1 represent perfect health and weights of 0
represent death. We conducted an analysis of the NDB to estimate a linear relationship
between HAQ score and EQ-5D preference weight (slope and intercept reported in Table
2.1). For example, the utility for a HAQ score of 2 is 0.567, compared to 0.739 for a
HAQ score of 1. The EQ-5D is a validated scale that allows one to map a health state
into a utility and this measure was collected from NDB patients. For adverse events we
used HRQoL weights derived from the medical literature.[38, 39, 40]
Costs
Direct and indirect costs were obtained from the literature and are reported in 2009
US dollars (Table 2.1). We used the medical care component of the Consumer Price
Index to adjust for inflation in medical costs.[41] We adopted a US societal perspective
and calculated total cost as direct cost plus indirect cost. In addition, direct cost was
assumed to have two components: drug-related and-disability related.
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We estimated the semi-annual cost for nonbiologic therapy from previous analyses.[42,
43] We used a weighted average approach to aggregate individual nonbiologic costs into
a single estimate. The weights were calculated from the NDB drug utilization patterns.
The costs of biologics costs were estimated from the Red Book.[44] We accounted for
the medication and administration costs. Costs of medications were based on the med-
ication unit cost, dose and frequency of administration. Similarly, administrations of
an intravenous biologic were based on infusion frequency. We assumed that the dosages
of etanercept, adalimumab, and rituximab were constant over time. However, those of
infliximab and abatacept were allowed to increase.
In addition to medication costs, each unit increase in HAQ was associated with
$1,500 increase in direct cost relative to a HAQ score of 0.[24] In addition, we assigned
a short-term cost to serious infection,[38] non-melanoma skin cancer,[45] and a minor
adverse event. In sensitivity analysis, we incorporated the treatment costs associated
with lymphoma.[40]
Indirect costs were also included as productivity loss for those patients 65 years or
younger. We calculated the indirect cost as a function of HAQ based on a previous
approach.[46] We estimated the indirect cost using this formula: indirect cost = change
in work capacity x average wage. Where change in work capacity = 0.21 x change in
HAQ [47] A six-month average wage was derived from 2009 annual average wages from
the Department of Labor Statistics.[48]
2.2.6 Sensitivity Analysis
In the base-case analysis, we compared the incremental cost-effectiveness ratio (ICER)
of each of the 60 biologic strategies to the same nonbiologic base-case strategy. Next,
we conducted one-way sensitivity analysis by varying the model parameters between
their lower and upper confidence bounds. We performed additional what-if analyses on
14
three key parameters in the model: biologics initial benefit, HAQ progression rate for
biologics and nonbiologics, and biologic costs.
2.3 Results
We found that, on average, treatment with biologics resulted in 0.01 to 0.34 QALYs
greater than treatment with nonbiologics, depending on the biologic sequence. The
most effective sequence of biologics was a strategy starting with etanercept, followed
by infliximab, then adalimumab (EIA) (0.34 QALYs). The incremental lifetime cost of
biologics ranges from about $130K to $250K compared with nonbiologics. All biologic
sequences were similar in terms of their cost-effectiveness. Biologic strategies starting
with older biologics (e.g., etanercept and infliximab) were slightly more effective than
strategies starting with newer biologics (e.g., rituximab and abatacept). The sequence
with the lowest ICER compared with nonbiologics was the EIA strategy at $0.5 million
per QALY, a value that is well above willingness to pay (WTP) thresholds considered
acceptable.
Table 2.2 presents the one-way sensitivity analyses of the models input parameters.
Our base-case results were robust to all sensitivity analyses scenarios. In all of these
scenarios, the ICER of EIA was greater than 0.3 million/QALY.
We conducted further analyses on three key parameters in the model: the initial
HAQ improvement following biologics, HAQ progression rate for both biologics and
nonbiologics, and the cost of biologics. For our base-case analysis we assumed that the
progression rates estimated from the NDB reflected both the short- and long-term effects
of treatment. However, many RCT-based CEAs incorporate a short-term benefit in
addition to long-term delay of disease progression. Figure 2.2(a) shows a representation
of our base-case assumption, where the average HAQ progression for simulated patients
all starting at HAQ 1.2 is shown under two scenarios: nonbiologics compared to the
15
EIA biologic strategy. Figure 2.2(b) illustrates the mean HAQ over time under the
assumption of a 0.25 absolute initial HAQ improvement, whereas Figure 2.2(c) shows
the average HAQ over time under the assumption that the HAQ progression rates are
twice that of our base-case assumption. The area between the curves is proportional to
the incremental effectiveness of biologics relative to nonbiologics.
In a two-way sensitivity analysis, we investigated the impact of reducing the util-
ity/HAQ conversion from -0.172 to -0.234, and assuming no HAQ progression while
on biologics. Reducing the HAQ/utility conversion factor reduced the ICER from
$0.5M/QALY to $0.4M/QALY while assuming no HAQ progression during biologics
use reduced the ICER to $0.3M/QALY, and reducing both parameters resulted in an
ICER of $0.2M/QALY.
Figure 2.3(a) presents the sensitivity analysis as we varied the initial benefit of
biologics from 0 to 1. If the initial benefit were increased to 0.25 HAQ, the ICER drops
rapidly and EIA becomes cost-effective at a WTP threshold of $100K/QALY. Figure
2.3(b) illustrates the impact of a long-term assumption on the sensitivity of ICER of
the EIA strategy. Here, we increased HAQ progression rates for both biologics and
nonbiologics by the same factor. Most RCT-based CEA include a HAQ progression
rate that is generally higher than observed in the NDB. As HAQ progresses at a faster
rate for both biologics and nonbiologics, the ICER of EIA drops dramatically. This is
likely due to nonbiologics having a higher base-case progression rate; multiplying the
HAQ progression rates for both biologics and nonbiologics by the same factor widens
the absolute difference between the two, as illustrated in 2.3(c).
In Figure 2.3(c) we examined the ICER sensitivity due to reduction in the cost of
biologics. The relationship between ICER and biologics cost reduction is illustrated. As
the biologics cost decreased relative to the base-case cost, the ICER of EIA decreases
rapidly. At around 70% of their base-case costs, biologics start to become cost-effective
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at a WTP threshold of $100K/QALY. At around 85% reduction, EIA appears cost
saving.
2.4 Discussion
Based on real-life RA patient experience, we simulated the long-term cost-effectiveness
of biologics compared to nonbiologics from a US societal perspective. To mimic current
biologic administration patterns, we relied primarily on the NDB as the main data
source. We utilized published estimates and conducted further analyses of the NDB
in order to obtain parameter estimates that were difficult to locate. We were able
to compare a large number of the most frequently used biologics, take into account
discontinuation patterns of these drugs, and their potential adverse events. Using these
data, we found biologics strategies to be slightly more effective and significantly more
expensive than nonbiologics. As a result we observed very high ICERs for biologic
strategies. We investigated varying sequences of the five most prescribed biologics:
infliximab, etanercept, adalimumab, abatacept and rituximab.
Most biologic sequences that we investigated were similar in their lifetime costs
and benefits. However, we found that strategies starting with rituximab or abatacept
were generally less effective than those starting with infliximab or etanercept. This
effect may partly be due to data limitation since rituximab and abatacept are relatively
newer and less likely to be the first biologic a patient uses. More patients who have
already failed the older biologics may switch to these newer biologics causing them to
appear less efficacious in the NDB. Further investigation is required when more biologic
nave patients receive these newer biologics as the first line of therapy.
Using long-term data from real-life practices, we were unable to observe the ICERs
reported by most RCT-based CEAs. While we found the lifetime incremental costs
similar to those reported in the RCT-based CEAs, we found the incremental health
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benefits of biologics to be significantly less than those reported in most studies. We
believe that the difference in health benefit between our study and RCT-based CEAs
has two components. The first was previously explained by Wolfe and colleagues,[5]
who showed that HAQ score improvement from RCTs were much greater than those
from observational studies. The reason for this was later explained to be due to RCT
eligibility criteria and the timing of the measurement.[27] The second component, and
perhaps the more important one, is how disability is converted to QALY in a trial
setting. Most trial-based CEAs measure QALY as the difference between the HRQoL
measurement at the beginning of a trial and the first measurement. Thus, these analyses
extrapolate the initial trial flare to be lasting an entire model cycle length, generally six
months. However, it is known that HAQ worsening in trials corresponds to a temporary
flare in disease severity. The six-month cycle may be significantly longer than the
duration of the temporary flare. Thus, the calculated QALY in RCTs can be potentially
many folds larger than the actual real-life improvement.
Since we focused on long-term outcomes, we assumed that a pooled estimate of
HAQ progression rate over a twelve year window in the NDB is sufficient to capture
all biologic and nonbiologics benefits (including short-term and long-term benefits).
Therefore, in this analysis we used HAQ progression rate solely to reflect biologic and
nonbiologic benefits. This is a major difference between our approach and prior CEAs,
particularly those based on RCTs. The RCT analyses are based on short-term data
and often assume that biologic and nonbiologic benefits have an immediate and long-
lasting HAQ improvement (short-term benefit), and the second component is through
a slower disease progression for those who receive biologics (long-term benefit). In a
sensitivity analysis we investigated the impact of incorporating short-term benefits and
altering long-term benefits similar to these RCT-based analyses. As expected, most
of the difference between our results and those from RCT-based CEAs disappeared.
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Since our analysis reflects the differential HAQ progression rates among biologics and
nonbiologics users, our results may bias against biologics. To account for this bias,
we investigated the cost-effectiveness of biologics under increased biologics benefit. In a
what-if scenario, we investigated the sensitivity of ICER while increasing biologics short-
term benefit. Although, this change caused biologics to be cost-effective, the immediate
benefit of biologics had to be relatively high for biologics to be cost-effective.
Long-term data on newer biologics, e.g.: abatacept and rituximab are limited. We
found treatment strategies that start with these newer biologics to be less cost-effective.
This can perhaps be explained due to some of those who take the newer biologics
may have already tried, and failed, the older biologics making them more prone to be
unresponsive to other agents.
Another limitation of the basecase analysis is that we assumed that HAQ progression
is independent from discontinuation due to inefficacy. In a sensitivity analysis, we build
a correlation between biologics discontinuation and HAQ progression. We allowed 50%
increase in the likelihood of discontinuing due to inefficacy if the progression on biologics
was higher than nonbiologics, and 50% decrease otherwise. As a result, the incremental
benefit increased from 0.30 to 0.35, and the ICER decreased from about $0.5 to $0.45
Million per QALY. Thus, building this correlation had a small impact on the results.
This is because less than 4% of patients who are on biologics discontinue due to inefficacy
in the NDB.
Since our analysis was based on observational data, it is difficult to eliminate se-
lection bias (i.e. the sicker patients may receive biologics). The original analysis that
we based our study on controlled for baseline characteristics that are likely to confound
the effect of treatment [29]. However, this may not be complete and there may still
exist other confounder or unobservable variables that may influence these results. To
account for selection bias, in a sensitivity analysis we assumed the best case scenario
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that biologics can stop HAQ progression. The ICER was still significantly above ranges
often considered acceptable by many health-care agencies.
Observational data may not be devoid of measurement timing bias. RA patients
in the NDB complete the questionnaire voluntarily. Although the questionnaire is sent
at regular six months intervals, the timing of the response (measurement timing) may
not be uncorrelated with receiving the biologics (decision timing). For example, those
who suffer a flare may be unable to fill the questionnaire until after they received the
biologic. As a result, these patients may report a lower HAQ score than what they have
experienced when they received the questionnaire.
We were unable to conclude that biologics were cost-effective in patients with RA
from a US societal perspective. Our results were robust to extensive sensitivity analyses.
Although biologics may be cost-effective in RCT settings, in real-life they may not have
been restricted to patients that fulfill the RCT eligibility criteria. These eligibility
criteria and several short-term and long-term assumptions made in RCT-based CEAs
may cause biologics to appear more cost-effective than they observed in real-life settings.
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2.5 Tables
Table 2.1: Parameter Estimates Used in the Model
Parameter Value Range Source
Starting age (year) N(47,14)a 18 – 80 b
Starting HAQ N(1.2,0.76)c 0 – 3 b
Annual HAQ progression rates (HAQ/year) [29], b
Nonbiologics N(0.018,0.010) 0 - 0.038
Etanercept N(0.007,0.0055) 0 - 0.018
Infliximab N(0.006,0.0055) 0 - 0.012
Adalimumab N(0.01,0.0085) 0 - 0.027
Abatacept N(0.015,0.008) 0 - 0.031
Rituximab N(0.012,0.010) 0 - 0.032
Excess HAQ-related annual mortality rates relative to HAQ 0 (per 1000) [26]
HAQ [1, 2, 3] [0.5, 1.8, 5.5]
Six-month probability of adverse events
Serious infections NB 0.017 Reference [32]
Serious infection Biologics 0.034 0.022 − 0.051 [32]
Nonmelanoma skin cancer NB 0.002 Reference [32]
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Parameter Value Range Source
Nonmelanoma skin cancer B 0.007 0.003 − 0.019 [32]
Minor adverse events - B 0.01 0.005 − 0.02 Assumed
Case fatality rate due to serious infection 0.36 0.225 − 0.377 [33, 34]
Conditional probabilities of discontinuation by cause a
Inefficacy 0.415
Major adverse event 0.206
Out-of-pocket cost/other 0.379
Health-related quality of life (utility) weights, timeframe
Intercept, utility = f(HAQ) 0.911 0.77 - 0.911 a
Slope, utility = f(HAQ) −0.172 −0.234 – (−0.172) a
Serious Infection 0.42 0.4 – 0.8 [38]
Nonmelanoma skin cancer 0.996 0.984 – 1.0 [39]
Lymphoma 0.83 0.30 − 1.0 [40]
Minor AE HRQoL weight 0.99 0.98 – 1.0 Assumed
Six-month cost of treatment (2009 US Dollars)
Nonbiologics $1,203 [42]
Etanercept $11,371
Infliximab $12,946 10,004 - 17,067 [43]
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Parameter Value Range Source
Adalimumab $11,371
Abatacept $15,652 14,323 - 18,730
Rituximab $13,173
Six-month cost of adverse events
Serious infection $5,780 $9,000– $18,400 [38, 49]
Non-melanoma skin cancer $1,200 $992 – $1,460 [45]
Minor adverse event $100 $50 – $200 Assumed
Indirect Cost
Slope, HAQ and work capacity −0.21 −0.2515 – (−0.0838) [47]
Median wage in 2009 $22,776 [48]
Notes: NB = nonbiologics; B = biologics; HRQoL = health-related quality of life; a = Age restricted between 18
and 80 years.; b = NDB analysis; c = HAQ restricted between 0 and 3.
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Table 2.2: One way sensitivity analysis
Scenario Parameter Change ∆Cost ∆QALY ICER
Base case - 170,300 0.34 500,900
Intercept, utility = f(HAQ) LB 0.77 170,300 0.31 549,300
Slope, utility = f(HAQ) LB -0.234 167,200 0.45 371,500
Utility skin cancer LB 0.984 170,300 0.35 486,500
Utility - severe infection UB 0.8 170,300 0.31 549,300
Risk of skin cancer on biologics LB 0.003 171,200 0.35 489,000
Risk of skin cancer on biologics UB 0.019 168,300 0.34 495,000
Risk of serious infection on biologics LB 0.022 171,700 0.35 490,500
Risk of serious infection on biologics UB 0.051 167,500 0.33 507,700
Risk of lymphoma on biologics UB 0.0006 166,900 0.25 667,800
Risk of minor adverse events LB 0 170,200 0.51 333,700
Risk of minor adverse events UB 0.01 170,400 0.3 568,000
Slope of wage function LB -0.25 169,400 0.34 498,300
Slope of wage function UB -0.17 171,200 0.34 503,400
Cost of skin cancer treatment UB 1,460 170,300 0.34 500,800
Cost of serious infection treatment LB 9,000 169,500 0.34 498,600
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Scenario Parameter Change ∆Cost ∆QALY ICER
Cost of serious infection treatment UB 18,400 167,300 0.34 492,100
Cost of minor adverse event treatment LB 50 170,300 0.34 500,700
Cost of minor adverse event treatment UB 200 170,400 0.34 501,100
∆Cost = incremental cost; ∆QALY = incremental effectiveness; ICER = incremental cost-effectiveness ratio; LB
= lower bound of parameter value; UB = upper bound.
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2.6 Figures
Figure 2.1: A simplified outline of the decision tree.
The model compares biologic strategies to a base-case nonbiologic strategy. A hypothetical patient is simulated through all
strategies simultaneously. In the base-case nonbiologic strategy, the patient continues to receive nonbiologics treatment. In the
biologic arm, the patient starts with the first biologic, and continues if there is a minor adverse event (AE). In case of a serious
AE or high out-of-pocket cost, the patient discontinues the biologic. In case of inefficacy, the patient switches to the next biologic
in the sequence. These alternatives repeat while on the second and third biologics. The patient discontinues biologics if the third
biologic is ineffective.
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Figure 2.2: HAQ progression for a biologic (EIA) and nonbiologic (base-case) strategies.
HAQ is plotted on the y-axis and time since biologic decision is plotted on the x-axis. (A)
represents the basecase analysis. An immediate improvement in HAQ was introduced in (B),
and HAQ progression rates were doubled in (C).
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Figure 2.3: ICER sensitivity.
Incremental cost-effectiveness ratio (ICER) Sensitivity is shown for (A) initial HAQ improve-
ment, (B) HAQ progression rates, and (C) biologics cost. In all plots, ICER is plotted on the
y-axis. The x-axes represent the initial decrease in HAQ, percent increase in the HAQ progres-
sion rate, and biologics cost percentage in A, B, and C, respectively. The base-case values for
each parameter is indicated with an ×. In the base-case analysis we assumed no immediate
improvement in HAQ (A), biologics and nonbiologics progression as reported in Table 1 (B),
and biologics full cost (C). An immediate and sustainable HAQ improvement of more than 0.25,
a HAQ progression rates of 8 folds higher than the base-case, or a reduction in biologics cost
by 30% can reduce the basecase ICER to $100K/QALY. Biologics became cost-saving when at
85% of their original costs.
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Chapter 3
Implications of Using Effectiveness
Instead of Efficacy on the
Cost-Effectiveness of Biologics in
Rheumatoid Arthritis: A Novel
Meta-analytic Approach
Background. Systematic reviews of the cost-effectiveness of biologics in rheumatoid
arthritis (RA) are limited to a description of the models and their findings. These re-
views do not analyze the information presented in the sensitivity analyses which provide
important insights into these models.
Purpose. To systematically review prior cost-effectiveness analyses (CEA)s of biolog-
ics compared to nonbiologics in RA, and study the implications of using clinical practice
data instead of randomized clinical trial (RCT) on the results of RCT-based CEAs.
Methods. We reviewed the literature for CEA in adult-onset RA. We investigated the
association between the funding source and the ICER and developed a meta-analytical
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approach that utilizes the published sensitivity analysis results from these CEAs. In
addition, we obtained parameter estimates from the National Data Bank for Rheumatic
Diseases (NDB) for the six most commonly reported model parameters, and tested the
implications of using these estimates on the results of RCT-based CEAs.
Results. Of the 15 CEAs that were sponsorship by the industry, only one produced
unfavorable results compared to 5 out of 11 non-industry sponsored studies. In addition,
using the NDB estimates doubled the ICER form RCT-based CEAs. Overall, the most
important input parameter was the initial Health Assessment Questionnaire (HAQ)
improvement following biologics. This parameters estimate was 71% lower in the NDB
compared to the mean estimates from the RCT-based CEAs. Using the NDB estimate
for this parameter increased the average ICER by 139%. The second most influential
factor was the background HAQ progression rate. NDB estimate of this parameter
resulted in 34% increase in the ICER. Among all parameters analyzed, only the HAQ
progression of biologics in the NDB reduced the ICER all other parameters increased
the ICER.
Conclusion. Funding sources and data sources have important implications on RCT-
based CEA analyses. This study is the first that utilizes published sensitivity analyses
results to reveal the characteristics of CEA and uses this information to investigate the
impact of data source on the findings.
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3.1 Background
Rheumatoid arthritis (RA) is a chronic debilitating condition that affects 1% of the
adult US population. RAs presentation may vary, but it generally affects the synovial
membrane of joints and causes progressive pain, swelling, lower quality of life and pre-
mature death. In addition, RA has an important implication on the society from direct
resource use and indirectly through productivity loss and caregiver costs.
Diseases modifying anti-rheumatic drugs (DMARDs) greatly improved the prognosis
of RA by slowing joint damage and improving the quality of life. DMARDs include
a wide class of medications such as methotrexate, sulfasalazine, hydroxychloroquine
and corticosteroids. Biologic DMARDs may even provide the best improvement in the
quality of life and decelerating the joint damage. However, biologics are significantly
more expensive than nonbiologic DMARDs. As a result, guidelines often recommend
their use after failure of nonbiologic DMARDs.[2, 3]
Cost-effectiveness of biologics in treating RA is widely recognized by many agencies
(e.g., National Institute of Health) as a high research priority area.[4] Cost-effectiveness
analyses (CEA) investigate whether biologics benefit through improving quality of life,
increased productivity, and extending life can offset the direct drug cost through math-
ematical modeling. However, the results from these studies are largely controversial
because they are mostly funded by the industry and use short-term RCT efficacy data in-
stead of clinical practice effectiveness.[50] In a previous meta-analysis of the CEAs of bio-
logics, all studies that were supported by industry reported favorable outcomes.[4] In ad-
dition, an analysis of the Tufts CEA Registry database (available online at http://tufts-
nemc.org/cearegistry) found an increased likelihood of reporting favorable outcomes in
industry sponsored CEAs.[12] Another study found no unfavorable conclusion for stud-
ies that were sponsored by the pharmaceutical industry which formed nearly 70% of the
published analyses.[51] However, neither of these reviews were specific for RA. In this
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study we analyze the association between industry sponsorship on CEA of biologics in
RA.
Furthermore, randomized controlled trials (RCT) show greater efficacy for biologics
in RA compared to clinical practice effectiveness from observational studies.[5, 6] The
initial health states of RCT participants may not represent the health states of patients
in clinical practice. To be eligible to participate in an RCT, RA participants must meet
certain disease activity that exclude the majority of biologic eligible patients.[7] There-
fore, RCT show a larger improvement in disability following biologics administration.
In addition, participation in RCT has shown to temporarily improve the health status
of the participants due to the Hawthorne effect.[10] In a study, half of the improvement
observed during the RCT period disappeared immediately after the trial terminated.[10]
Therefore, the results from RCT-based CEAs are believed to cause biologics to appear
more cost-effective than they are in clinical practice.[8]
Because these models are essentially black-boxes, it is challenging to test how their
findings change using updated clinical practice data without access to the original mod-
els. Even with the access to these models, it is challenging to reconcile their param-
eters and their results. In order to understand the implication of using observational
data in RCT-based cost-effectiveness analyses (CEA), we needed a meta-analytical ap-
proach capable of combining information from multiple RCT-based CEAs. The task of
combining information from multiple CEAs is of particular importance to policy and
decision makers.[52, 13] However, there is no meta-analysis study that involves statis-
tical analysis of different CEAs. Studies that provide descriptive analysis of CEAs are
rather systematic reviews rather than meta-analyses.[52] Most CEAs provide important
insight into the models through sensitivity analysis tables and figures (e.g., tornado di-
agrams). However, this information in a row format is of limited use, since most studies
use different parameter values.[13] As a result these meta-analyses are often limited to a
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descriptive comparison of the sensitivity analyses, including a recent systematic review
of biologics CEAs in RA.[4]
In this study, we adopted a metamodeling approach that utilizes the published sen-
sitivity analyses to reveal the underlying dynamics of these models. Our metamodeling
approach was a linear approximation of the relationship between the model input pa-
rameters and the ICERs. Metamodeling is widely used as add-on to simulation models
because it removes the need for the simulation model.[53] To the extent of our knowledge,
this analysis is the first that utilizes the important information provided in sensitivity
analysis to compare CEAs analytically.
3.2 Methods
3.2.1 Literature search
We conducted an electronic search of the National Health Services Economic Evalua-
tion Database (second quarter 2013) and the Tufts Medical Center Cost-Effectiveness
Analysis Registry (1976 to June 2013). We identified 203 citations containing the
phrase rheumatoid. 153 articles were excluded because (1) they compared other med-
ication or interventions, (2) were not economic evaluations, (3) compared biologics to
other biologic agents[28, 54, 55], (4) did not report cost per quality adjusted life years
(QALY)[56, 47], or (5) were about juvenile arthritis, or other non-specific arthritis that
did not include specific results for RA.
We retrieved the full-text of 31 CEAs that compared biologics to nonbiologics for RA
patients. From each study, we retrieved study variables, such as currency type, currency
year, ICER of a biologic vs. a nonbiologic and the studys funding source (Table 3.1).
The CEA Registry provides approximate ICERs, but exact ICERs were obtained
from the articles directly. If a study provided ICER for more than one biologic strategy,
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we included the ICER of the biologic sponsored through funding agency if applicable.
If no such funding resource existed, we used the ICER of the first reported biologic.
Similarly we included ICERs from societal perspective, but when unavailable we used
the payers perspective. Furthermore, if ICERs over multiple time periods were provided,
we used the ICER over the longest duration.
Next, we obtained the published sensitivity analysis results to reveal parameter im-
portance. Among the 31 article, 17 reported one-way sensitivity analysis (OWSA) and
used efficacy data from RCTs. OWSA is commonly reported in economic evaluations
in which the model outcome is repeatedly re-evaluated while changing one parameter
at a time. Thus, OWSA can provide important insight into the behavior of a model.
These studies reported the OWSA either in a tabular format or as a tornado diagram.
For each study, we retrieved the values of six parameters that were most commonly in-
cluded in sensitivity analyses. These parameters were: (1) the initial Health Assessment
Questionnaire Disability Index (HAQ) improvement following biologics, (2) HAQ/utility
conversion factor for calculating HRQoL from HAQ score; (3) HAQ progression while
on biologics, (4) background HAQ progression rate, (5) increased mortality rate for
each unit increase in HAQ, and (6) the standardized mortality rate which measures
the overall increase in risk of mortality due to RA compared to the general population.
Most studies either reported SMR or RR of mortality by HAQ. One study[27] included
both, which was considered double counting of the mortality effect by another study[42].
Not every study reported all input parameters, but for those reported, we retrieved the
resulting ICER associated with each parameter value.
Most CEAs reported OWSA to illustrate the robustness of the results. As a result,
they were less consistency among the type of inputs and input scales (relative or abso-
lute) chosen in these analyses. For example, several studies reported the HAQ/utility
conversion factor directly; others reported the HRQoL as a regression equation of
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HRQoL on HAQ. In these regression equations, two parameters are changed simul-
taneously: the intercept and the slope of HAQ. For example, three of these regres-
sions reported in many sensitivity analyses were HRQoL = 0.77 − 0.17 × HAQ in [57],
HRQoL = 1.12 − 0.19 × HAQ in [58], and HRQoL = 0.72 − 0.28 × HAQ in [59]. To
isolate the HAQ/utility conversion factor from these equations, we estimated the value
of ICER while holding the intercept constant at its base-case value. Then, we recom-
puted the conversion factor while adjusting for the regression intercept. Other studies
reported non-linear function between HAQ and HRQoL. For example, Soini and Halli-
nen used a non-linear function of EQ5D = 0.82 − 0.1 × HAQ − 0.07 × HAQ2.[60] we
transformed this function using the best fitting line over a HAQ range of 0-3, in the
form HRQoL = 0.9215− 0.31×HAQ.
A number of analyses, especially those presenting the results as tornado diagrams
were unspecific to whether the low value of an input was associated with the low value of
ICER or vice versa. In these cases we made a decision of the direction of the association.
We confirmed these relationships to make sure the direction of these associations were
logical and consistent across studies.
3.2.2 Input effect size (IES)
We used the published sensitivity analysis results to calculate the input effect sizes
(IES) in each study for the reported parameters of interest. We defined IES as the
percent change in ICER due to one percent change in an input from its baseline (i.e.,
IES for an input x = % change in ICER / % change in x from its baseline value).
Next, we calculated the average IES estimates for each input across all studies that
reported the same parameter. The number of studies that examined each parameter
varied from two (initial HAQ improvement) to seven (Background HAQ progression
rates). (Appendix A presents the detailed calculation of the average input parameter
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values and the associated IES for the selected parameters from the RCT-based CEAs).
Some studies only reported the relative changes from the parameters baselines without
providing the base-case values. In these cases, we were able to compute the IES values.
In order to examine the impact of replacing RCT efficacy with observational effec-
tiveness in these models, we replaced the model parameter estimates with those obtained
from the National Data Bank for Rheumatic Diseases (NDB). We calculated percent de-
viation of the NDB estimates from the mean parameter estimates from the RCT-based
CEAs. Then, we computed the predicted percent change in ICER when observational
estimates are used as the produce of IES and NDBs percent deviation.
3.3 Results
Figure 3.2 compares the reported ICER by the CEAs funding sources. The results are
presented in US dollars using an average exchange rate and updated to 2013 US dollars
using the 2013 Consumer Price Index Data.[61] The original currency type and year are
also presented. Fifteen studies were funded by industry, ten indicated a non-industry
source, and the funding sources were not reported in five studies. Among all industry
sponsored studies, only two studies[62, 63] reported unfavorable ICERs, and only one[62]
had unfavorable conclusion compared to 8 that reported unfavorable ICERs among 10
non-industry funded studies. All studies with unknown funding reported favorable
ICERs.
Table 3.2 presents the impact of replacing parameters used in these studies with
NDB-based estimates. Overall, the IES and RCT-based inputs values were similar across
all RCT-based CEAs except for the parameters representing mortality [the relative
risk of mortality for each unit increase in HAQ (IES mean = +0.04 and IES standard
deviation = 0.23), and RA specific mortality (IES mean = +0.32 and standard deviation
= 0.88). See appendix A].
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The most influential input parameter was the initial HAQ improvement with an IES
of -1.96, indicating that ICER decreases by about 2% for each 1% increase in HAQ
improvement from the baseline. The second most influential factor was the background
HAQ progression with an IES of -0.5. This is an important finding since background
HAQ progression is not directly related to biologics treatment and thus not expected
to change the ICER dramatically.[50] This table also presents the NDB-based estimates
for these model parameters. The largest deviation of NDB estimate versus the RCT-
based CEA estimates was the Mortality RR for each unit increase in HAQ with a %
deviation (%D) of 79% indicating NDB-based estimate was, on average, about 80%
higher than the values used in RCT based studies. However the IES of this input was
relatively small, and the overall estimated ICER change was about +3% if NDB-based
estimate was used instead of the mean estimate from the RCT-based studies. The NDB
values for the initial HAQ improvement, Background HAQ progression and biologics
HAQ progression were all about 70% less than the values used in the RCT-based CEAs.
Overall, using NDB estimates instead of RCT-based CEA sources resulted in nearly
tripling the ICERs reported by these studies (an increase of +99%).
Figure 3.3 presents the IES for the six selected input parameters. The IES varies
significantly from one study to another, indicating a high degree of structural inconsis-
tencies among these CEAs. For example, the IES for the background HAQ progression
rate varied between −200% to 0%. This trend is also visible for the other parameters.
However, the IES directions were all similar, except for the IES of the mortality relative
risk per unit HAQ which was positive for some studies and negative for others.
3.4 Discussion
We reviewed the literature for published CEAs of biologics compared to nonbiologics,
and developed a novel approach of meta-analysis of CEAs. We investigated the impact
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of funding source on the CEA results and the implications of using real-life clinical data
instead of RCT efficacy in these analyses. We found a large variation in the reported
ICERs of biologics relative to nonbiologics. Analyses sponsored by industry were more
likely to report favorable ICERs than non-industry sponsored studies. These findings
confirmed the results of a prior analysis of the CEA Registry which also found indica-
tions for publication bias.[12] The current analysis is the first study that systematically
compares the impact of funding source of biologics in RA. Although a recent meta-
analysis specific to RA presented the funding source of these studies, it did not make
the connection between the funding source and the ICERs reported.[4]
We further investigated the parameter importance in the RCT-based CEAs and
the implications of using clinical practice effectiveness data instead of RCT efficacy
as sources of parameter estimates in these CEAs. We used the published sensitivity
analyses results that reported ICER sensitivity to six parameters related to short-term
HAQ improvement, long-term HAQ progression, HAQ/utility conversion factor and
RA related mortalities. Furthermore, we obtained estimates for these parameters from
clinical practices as observed from the NDB and used these estimates to predict the
impact of using clinical practice data on the results of RCT-based CEAs.
We defined IES as a new measure of CEA sensitivity. Because IES measures the
relative change in ICER, it can be compared across studies that use different currencies
or were conducted in different calendar years. IES also captures relative change in
the model parameters. Therefore, it can be used for studies that only report relative
sensitivity analysis (e.g., +/- 50% change from baseline) instead of absolute changes.
The initial HAQ improvement following biologics administration was overall the
most influential parameter. This parameter is also the most criticized in the literature
because it is directly related to the treatments and observational studies generally report
smaller improvements than RCTs. As a result, previous studies have questioned the
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generalizability of RCT-based CEAs to clinical practice.[7, 5] In addition, one study
found that the ICER almost doubled when using clinical practice effectiveness instead
of RCT efficacy data.[63]
The initial HAQ improvement only captures the short-term model assumptions. The
second most influential input was the background HAQ progression. This is an impor-
tant finding because background HAQ progression is not directly related to biologic
treatment and is generally equally applied to both the treatment arms in the CEAs. In
addition, we lack accurate estimates simply because long-term data do not exist.[5] The
NDB estimates were generally three times higher than the estimates used in the RCT-
based CEA. However this impact was partially offset by the HAQ progression while on
biologics. This is because the NDB estimate of this parameter was also about 70% less
than that reported in the RCT-based CEAs. Higher rates of progression reported in
RCT-based CEA may be due to the trials flare design and the regression to the mean
phenomenon.[29]
The HAQ/utility conversion factor also influenced the reported ICER significantly.
Our findings confirm a study conducted by Marra et al where the authors found that
different HRQoL instrument can significantly alter the conclusion of cost-effectiveness
analyses.[64] The authors compared the impact of using EQ5D, SF6D, and HUI3. SF6D
resulted in the largest ICER, while SF6D produced the lowest.[64] It is noteworthy to
mention that the HAQ/utility conversion factors reported by these authors were -0.29
and -0.13 when using the SF6D and HUI3, respectively. Our results confirm these
findings, because we used a conversion factor of -0.11 from the NDB compared to the
RCT-based CEAs which used an average conversion factor of -0.26 as a result the ICER
increased by 27%.
Unlike the other parameters, the HAQ-related mortality was contradictory among
the RCT-based CEAs. The base-case value for this parameter in RCT-based CEAs was
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(1.33-1.77), while the IES range was (-0.74-0.96), indicating that increased mortality
relative risk by HAQ were not consistent among studies. Although it is expected that
higher HAQ related mortality should decrease ICER due to higher QALYs, it is also
expected to increase the survivor cost during the gained years of life.
This approach has several important limitations. First, the accuracy of our results
is determined by the accuracy and consistency of sensitivity analysis reporting. Sensi-
tivity analysis is an approach to demonstrate the robustness of the results to parameter
uncertainty. As a result, current analyses do not adhere to a specific set of inputs to in-
corporate and report in the sensitivity analyses.[13] Several CEAs only reported relative
change in parameters without referring to the base-case values. Although, we were able
to calculate the IES, we were unable to incorporate the base-case values in our analysis.
In addition, several studies especially those used tornado diagrams did not indicate the
direction of ICER change relative to the input change. We believe that we overcome
some of these limitations and hope that future analyses will report on a minimal set of
parameters.
Second, since we relied on published OWSA, we are unable to capture the additional
effect of parameter interaction in these models. Interactions occur in multilinear models
when the parameters are located on the same decision branch. In addition, several
studies reported probabilistic sensitivity analyses only. IES cannot be computed from
PSA directly without some measure of parameter importance, such as the expected
value of partial perfect information (EVPPI).
Third, due to the small sample, we did not adjust for study populations in the CEA.
Several CEAs are specific by disease severity, duration, or prior DMARD failure, and
these factors are important in influencing ICERs. Although the study population may
impact the base-line ICER, we believe by measuring the relative change in ICER, we
control for most of the impact of study population. In addition, by aggregating all the
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results we are more likely capture an effect that can be generalizable to clinical practice.
3.5 Conclusion
This study sheds light on two important aspects of our current understanding of CEA
of biologics in RA: the association of funding source with the findings of these study
and the implications of using clinical practice data instead on the RCT-based CEAs
through a novel meta-analytic approach.
We found that using observational-based estimates for several common inputs in
RCT-based CEAs tripled the ICERs reported by these studies, causing biologics to
appear less cost-effective than originally thought. To our knowledge, this is the first
attempt to systematically reconcile the impact of using observational data instead of
RCT results on the CEA of biologics in RA.
As more long-term data becomes available and the quality of CEAs improves, we
become more certain on the true cost-effectiveness of these agents. We recommend
establishing a minimal set of required parameters that will help future analysts to com-
pare CEAs on the input level and better summarize their findings, and reconcile their
differences.
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3.6 Tables
Table 3.1: Summary Characteristics of Cost-Effectiveness Studies.
Author, year [ref.] Country Horizon Perspective Discounting Currency Data source
Bansback, 2005 [65] Sweden Lifetime Payer 3%, 3% EUR, 2001 RCT
Barbieri, 2005 [66] United Kingdom Lifetime Payer 6%, 1.5% GBP, 2000 RCT
Barton, 2004 [67] United States Lifetime Payer 6%, 1.5% GBP, 2000 RCT
Benucci, 2010 [68] Italy 1 Year Payer N/A EUR, 2008 OBS
Brennan, 2004 [27] United Kingdom Lifetime Payer 6%, 1.5% GBP, 2000 RCT
Brennan, 2007 [69] United Kingdom Lifetime Payer 6%, 1.5% GBP, 2003 RCT
Chen, 2006 [42] United States Lifetime Payer 6%, 1.5% GBP, 2004 RCT
Coyle, 2006 [70] Canada 5 Years Payer 5%, 5% CAD, 2004 RCT
Davies, 2009 [71] United States Lifetime Societal 3%, 3% USD, 2007 RCT
Farahani, 2006 [63] Canada 1 Year Payer N/A CAD, 2003 OBS+RCT
Finckh, 2009 [72] United States Lifetime Payer 3%, 3% USD, 2007 OBS
Jobanputra, 2002 [73] United States Lifetime Payer 6%, 1.5% GBP, 2000 RCT
Kielhorn, 2008 [74] United Kingdom Lifetime Societal 3.5%, 3.5% GBP, 2006 RCT
Kobelt, 2003 [57] Sweden 10 Years Societal 3%, 3% EUR, 2001 RCT
Kobelt, 2004 [75] Sweden 1 Years Societal N/A EUR, 2002 OBS
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Author, year [ref.] Country Horizon Perspective Discounting Currency Data source
Kobelt, 2005 [76] Sweden 10 Years Societal 3%, 3% EUR, 2004 RCT
Kobelt, 2011 [77] Sweden 10 Years Societal 3%, 3% EUR, 2008 RCT
Lekander, 2010 [78] Sweden Lifetime Societal 3%, 3% EUR, 2007 RCT
Marra, 2007 [64] Canada 10 Years Societal 3%, 3% CAD, 2002 OBS
Merkesdal, 2009 [79] Germany Lifetime Societal 3.5%, 3.5% EUR, 2008 RCT
Schipper, 2011 [62] Netherlands 5 Years Societal 4%, 4% EUR, 2009 OBS
Soini, 2012 [60] Finland Lifetime Societal 3%, 3% EUR, 2010 RCT
Spalding, 2004 [80] United States Lifetime Payer 3%, 3% USD, 2005 RCT
Tanno, 2006 [81] Japan Lifetime Societal 6%, 1.5% GBP, 2005 RCT
van den Hout, 2009 [82] Netherlands 2 Years Societal 3%, 3% EUR, 2008 OBS
Vera-Llonch, 2008 [83] United States Lifetime Payer 3%, 3% USD, 2006 RCT
Virkki, 2008 [84] Finland NA Payer N/A EUR, 2006 OBS
Welsing, 2004 [85] Netherlands 5 Years N/R 4%, 4% EUR, 2002 RCT
Wong, 2002 [86] Canada Lifetime Societal 3%, 3% USD, 1998 RCT
Yuan, 2009 [87] United States Lifetime Payer 3%, 3% USD, 2007 RCT
Discounting is presenting for cost and effectiveness, respectively; QALY=quality-adjusted life-year; RCT = ran-
domized clinical trial; OBS = observational data; EUR = Euro; GBP = Great Britain Pound Sterling; CAD =
Canadian dollar; USD = US dollar.
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Table 3.2: Change in incremental cost-effectiveness ratio (ICER).
Screened Parameters
IES Input Est. D ∆ICER Data sources
Mean s n R O (O-R)/R IES * D NDB RCT CEAs
Initial HAQ change -0.77 0.07 3 -0.89 -0.26 -71% 55% [8] [27, 81]
Annual Background
HAQ progression
-0.5 0.03 7 0.07 0.023 -69% 34% [29] [42, 27, 1, 71, 74,
83, 87]
HAQ/utility conversion -0.48 0.06 5 -0.26 -0.11 -57% 27% a [27, 60, 1, 74, 79]
Annual HAQ progres-
sion for biologics
0.37 0.01 5 0.03 0.008 -69% -26% [29] [42, 27, 1, 74, 76]
Mortality RR per HAQ 0.04 0.23 6 1.52 2.71 79% 3% [26] [42, 27, 83, 87, 86,
66]
RA-Specific Mortality 0.32 0.88 4 1.98 2.26 14% 5% [88] [27, 1, 79, 77]
Total change 99%
Notes: IES = input effect size; s = standard deviation; n = number of studies; RCT = randomized clinical trail;
R = RCT data source; O = observational data source; D = observational deviation from RCT; ∆ICER = change
in ICER due to using observational data; NDB = National Data Bank for Rheumatic Diseases; HAQ = Health
Assessment Questionnaire; RR = relative risk; RA = rheumatoid arthritis; a=regression analysis of EQ5D on
HAQ.
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3.7 Figures
Figure 3.1: Flow chart of study selection.
CEA = Cost-effectiveness analysis; NHS EED = National Health Services Economic Evaluation
Database.
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Figure 3.2: Distribution of incremental cost-effectiveness ratios (ICER) by funding source.
NICE = Application for the National Institute for Health and Care Excellence; N/R = not reported; CAD = Canadian Dollar;
EUR = Euro; GBP = UK Pound Sterling; USD = US Dollar; ICER = Incremental Cost-Effectiveness Ratio.
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Figure 3.3: Model Consistency among RCT-based CEAs
IES = Input effect size; HAQ = Health Assessment Questionnaire; RR = relative risk; RA = rheumatoid arthritis.
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Chapter 4
Is there a Window of Opportunity for
Biologics in Early Rheumatoid
Arthritis? A Cost-Effectiveness Analysis
Background. Although the concept of a window of opportunity for early treatment
of rheumatoid arthritis (RA) is widely recognized among rheumatologists, it is unclear
if biologics are cost-effective during this period.
Methods. We used a Markov decision process (MDP) to identify the optimal sequenc-
ing of biologics and nonbiologics for a hypothetical cohort of newly diagnosed 45-year-old
RA patients. RA health states were defined by the Health Assessment Questionnaire
(HAQ) quintiles. We identified transition probabilities for biologics and nonbiologics in
early RA (duration<3years) and established RA (duration> 3 years) from the National
Data Bank for Rheumatic Diseases (NDB). Health-related quality of life, RA-specific
mortality, and work disability were estimated as functions of the HAQ and were es-
timated from the NDB and the literature. Model outcomes were quality-adjusted life
expectancy and lifetime costs. We assumed a 6-month Markov cycle length and used
3% discount rate for all costs and benefits.
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Results. In the base-case analysis, biologics were not cost-effective at a willingness-
to-pay (WTP) threshold of $100,000/QALY and at biologics at their full cost. At 40%
of the cost, biologics were cost-effective in early RA with HAQ scores 1.0. In addition,
at this reduced cost, biologics were cost-effective for established RA with HAQ 1.875.
When biologic costs were further reduced by 75%, biologics became cost-effective for
early and established RA with HAQ 1.875.
Conclusion. We adopted a novel approach that combines operations research theory
and real-life RA treatment practices to investigate the most-cost effective timing of
biologics. The findings from this study suggests that (1) biologics are not cost-effective
at their full cost as observed in real-life practices in the US compared to WTP thresholds
often considered acceptable, and (2) that at reduced cost, biologics are more cost-
effective in early RA than later in the course of the disease. These results have important
practice and policy implications.
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4.1 Background.
Modern management of rheumatoid arthritis (RA) patients aims toward slowing dis-
ease progression through timely diagnosis and treatment with the goal of complete
remission.[18] Early diagnosis and treatment in the first few months after the disease
process starts are crucial to prevent permanent joint damage and deformity. Even
though this window of opportunity in early RA is not clearly defined[89], rheumatol-
ogists recognize its importance in improving quality of life, reducing work disability,
and preventing premature death.[16, 17] In one study, biologics were more effective in
slowing disease progression in early RA patients compared to established cases. The
disability improvement in both groups were rapid and sustained, but it was superior in
early RA.[90]
The American College of Rheumatologists (ACR) and the European League Against
Rheumatism (EULAR) continuously update the RA treatment guidelines to more ef-
fectively target this window by promoting early diagnosis and treatment.[91, 19, 20,
2] In these guidelines, synthetic (nonbiologic) disease modifying anti-rheumatic drugs
(DMARDs) such as methotrexate (MTX) are often recommended as first-line agents.
Biologic DMARDs are only indicated when remission or low disease activity are not
achieved with nonbiologics, or when patients have features of poor prognosis (See Ap-
pendix B).[18, 19, 20, 2, 3]
The main issue with biologics is their high price tag which is at the maximum of
the markets tolerance.[92] Meanwhile, providers are under constant pressure to pro-
vide biologics in early arthritis.[92] The high cost of biologics are argued to be offset
by the long-term improvement in quality of life, physical function, clinical and radio-
graphical outcomes, increased productivity, and reduced work disability.[93, 94, 95] For
example during the first 2-3 years of RA,. 20-30% of the patients were work disabled
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and within 10 years 50% of them were unable to work.[96, 97] However, the compara-
tive clinical and cost-effectiveness of biologics relative to nonbiologics in early arthritis
is controversial.[18] Current cost-effectiveness analyses (CEAs) are based on standard
decision trees that are incapable of handling a large number of possible treatment se-
quences and are mostly based on clinical trial data. For example Chen et al found the
incremental cost to effectiveness ratio of biologics compared to nonbiologics in early
arthritis to be four times higher in early arthritis compared to established arthritis.[42]
Another study based on observational data, concluded that biologics were cost-effective
only in a scenario in which all parameters were in favor of biologics and the biologics
costs were reduced by 75%.[72] However, these studies are based on standard decision
trees which compare a limited number of treatment sequences, and are inherently inca-
pable of identifying an optimal starting time for biologics if such timing exists.
This study aims at identifying the optimal timing of biologics from a societal per-
spective in real-life settings. Specifically, is there a window of opportunity during which
biologics are most cost-effective in early RA? To properly address this question, we
adopted an innovative approach by using tool from operations research, Markov Deci-
sion Processes (MDP), instead of a standard decision tree and we used the National
Data-Bank for Rheumatic Diseases (NDB) as the primary source of model inputs. The
NDB consists of detailed self-reported semiannual questionnaires from 28,960 commu-
nity RA patients from around the US.[11]
The main advantage of MDP is its ability to model sequential decisions. MDP has
been successfully used in recommending the optimal timing of liver transplantation in
treating chronic liver diseases and in the optimal timing of HIV treatment strategies.[15,
14] Despite its clinical relevance, powerful properties, and successful implementation,
this tool remains underutilized in clinical settings.[98] To the best of our knowledge, this
is the first study that uses MDP to identify the most cost-effective timing of biologics
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in RA.
4.2 Methods
We used an MDP approach to identify the optimal timing of biologics for a cohort of
newly diagnosed 45-year-old RA patients. Specifically, the MDP identifies the biologic-
nonbiologic sequence that maximizes the net health benefit1 (NHB) among all possible
sequences. MDP uses backward induction, which simply indicates that the MDP com-
putes the NHB from the last set of decisions (age 99.5 to 100), and determines which
decision resulted in the maximum NHB for every state. The algorithm then moves
backwards to the decisions at prior ages (99 to 99.5, 98.5 to 99, and so forth until age
45). During each cycle the MDP records the optimal decision at each state. At the end
of the simulation, the MDP outputs the optimal sequence of decisions for each state
and RA duration, starting at age 45.
Figure 1 outlines the structure of the MDP, which consists of a set of health states,
the decision of biologics versus nonbiologics, a set of transition probabilities among the
states, and a set of rewards (not shown). The MDP simulates the lifetime experience of
a cohort of newly diagnosed 45-year-old RA patients. We used six-month Markov cycles
for a total of 110 cycles. In each cycle, the patients in the cohort transition among the
various states. These transitions are dependent on the RA duration and the biologics
versus nonbiologic decision.
The health states in the MDP were defined by the Health Assessment Questionnaire
Disability-Index (HAQ) score (Table 1). The HAQ measures the upper and lower limb
functions relative to difficulty in performing daily tasks. HAQ is the primary RA clinical
outcome measure in most cost-effectiveness analyses because it correlates well with
1NHB is an alternative to incremental cost-effectiveness ratio (ICER). NHB measures the difference
between the actual benefit gained investing in an intervention and what could have been gained if we
instead invested in a marginally cost-effective strategy at the willingness to pay threshold.[99]
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mortality and both direct and indirect costs.[1] We defined six health states in the
MDP defined by the five HAQ quintiles observed in the NDB (higher quintiles indicate
worse disability) and an additional state for death.
Transitions among various health states were estimated from the number of RA
patients who transitioned among the HAQ quintiles in the NDB. To account for po-
tential confounding by indication, we restricted our sample to 28,209 newly diagnosed
RA patients who were biologic nave when they entered the NDB, but eventually re-
ceived biologics during the NDBs observation time. Table 2 shows the number of NDB
observations used to estimate the transitions among various HAQ quintiles. We used
an arbitrary cutoff of 3 years to distinguish disease progression in early arthritis from
established disease because disability in early RA is most likely due to acute inflamma-
tion rather than joint deformity which occur later in the disease process. There were
fewer available data to infer the transition probabilities in early RA patients compared
to established RA patients. In addition, there was more information on biologics use
versus nonbiologics use because of censoring those patients who never received biolog-
ics. We used the HAQ scores of these patients prior to and after initiating biologics to
infer their HAQ transitions during nonbiologic and biologic use, respectively (Table 3).
In addition, we used patient-specific cubic splines to correct for irregularities in NDB
response timing.[15]
Model estimates for health-related quality of life, costs, and RA-specific mortality
are shown in Table 1. Health-related quality-of-life weights were estimated from a
regression analysis of EQ5D (a measure of health status from the EuroQoL Group) on
HAQ and age from the NDB. Direct medical costs were obtained from the literature.
Indirect costs were calculated as the product of three terms: the increase in productivity
loss due to each unit increase in HAQ (0.2), the median wage for a full-time employee
(estimated at $22,770) [48], and the mean HAQ in each quintile. All costs were inflated
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to 2013 US dollars using the medical care component of the Consumer Price Index to
adjust for inflation in medical costs.[61] Both costs and benefits were discounted by 3%
annually. Death was modeled as an additional state. Background age-specific mortality
was obtained from the US life tables.[30] RA-specific mortality was obtained from the
literature and varied by HAQ.[26]
4.3 Results
Table 4 presents the optimal strategy by RA duration and HAQ quintile for early versus
established RA at various biologics cost assumptions. In the base-case analysis, we used
biologics full cost. At this cost, nonbiologics were the optimal choice regardless of the
RA durations or the HAQ quintile, indicating that the marginal benefits from biologics
were insufficient to offset their high costs as observed in real-life patients. At 40%
cost, biologics appeared cost-effective in early RA for the more disabled patients (HAQ
1.0). At this cost, biologics were also cost-effective for established RA with HAQ 1.875.
When biologics costs were further reduced to 25%, biologics appeared cost-effective
for early and established RA with HAQ 1.0. These results indicate that the marginal
cost to benefit ratio of biologics compared to nonbiologics may be higher in early RA
compared to established RA later in the disease process. For example, nonbiologic
would be the most cost-effective strategy for a patient who stays in quintile 2 during
early RA. However, if this patient transitions to quintile 3 during late RA, biologics
become the most cost-effective choice. In a benefit-only analysis, nonbiologics were still
more effective than biologics for established RA with HAQ <1.0. For all other cases,
biologics were more effective than nonbiologics.
Table 5 presents the simulated outcomes of the most cost-effective strategy for a
cohort of 45-year-old RA patients. The results are shown at full biologics cost, as well
as reduced costs of 40% and 25%. Those who start at higher HAQ quintiles tend to
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spend more time at higher disability levels as shown in Figure 2 which illustrates the
cohorts dynamic at ages 45, 48, 60, 80 and 100 years in the various health states. At
age 45, the cohort is equally distributed among the HAQ quintiles. At age 48, the
majority of the cohort (35%) resides in the first quintile, which may partly be caused by
regression to the mean.[29] Later in life the cohort resumes a more uniform distribution
among various states. Meanwhile, as the simulation progresses, an increased proportion
of the original cohort dies and by age 100, the majority of the cohort will be in the
dead state. As a result of this cohort dynamic, the lifetime benefits are lower and the
costs are higher in the higher quintiles. Because in the base-case analysis biologics were
not optimal, the higher costs associated with the high HAQ scores are due to non-drug
costs and indirect costs rather than drug costs. Reducing biologics cost decreases the
lifetime costs of the optimal strategies. These cost reductions are relatively larger in
the higher HAQ scores. At reduced biologics costs, the biologic costs explain part of
the difference in the lifetime costs among the HAQ quintiles because more patients in
these states receive biologics compared to the lower quintiles.
In another sensitivity analysis, we examined the cohorts outcome while varying the
starting age between 35 and 55 years. Our findings were robust to these changes.
Nonbiologics were the optimal choice in early and established RA and for all HAQ
quintiles. At reduced biologics costs, biologics were more cost-effective in early arthritis
compared to established RA.
We also varied the cutoff time point that distinguishes early versus established RA
from 2 to 5 years. This analysis allowed us to examine the impact of this arbitrary cutoff
value on the cost-effectiveness of biologics. For example, biologics were cost-effective in
early RA at reduced costs of 50%, 45%, 40% and 20% when using 2, 3, 4 and 5 years
as cutoff values, respectively. Cutoffs values beyond 5 years were unable to capture a
different cost-effectiveness value of biologics in early arthritis. These results indicate
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that the RA progression during early arthritis is different than established arthritis and
biologics modify these progressions at different rates than nonbiologics.
4.4 Discussion
Although the concept of a window of opportunity for early treatment is widely recog-
nized among rheumatologists, it is unclear if there is a window of opportunity during
which biologics are most cost-effective in early RA. More often clinicians are faced with
the decision whether to start biologics in early arthritis or wait until the nonbiologics
were tried and failed. To identify the most cost-effective timing of biologics, we adopted
a novel approach that combines operations research theory and real-life RA treatment
practices. In the base-case analysis, we found (1) that biologics were not cost-effective
at their full cost compared to WTP thresholds generally considered acceptable, and (2)
that biologics were marginally more cost-effective in early RA rather than later in the
course of the disease. These results directly address the cost considerations involved in
initiating biologics in early arthritis. Our base-case analysis was robust to variations in
WTP thresholds between $100K-250K/QALY.
Our approach improves upon prior CEAs in two important ways. First, we used
observational data to represent real-life RA patient transitions among various HAQ
states. Most prior CEAs of biologics in RA are based on efficacy from clinical trials
instead of real-life effectiveness. The effectiveness of biologics in real-life practices is
lower than the efficacy observed in clinical trials.[8, 7] Wolfe et al. (2004) summarizes
the problems of estimating efficacy from RCT data as:[8] (1) patients experiencing
temporary worsening of symptoms may be overrepresented in RCTs due to eligibility
criteria, (2) the treatment options compared in RCTs are rarely applicable to clinical
settings, and (3) RCT duration is typically shorter than the duration of RA observed
in real-life.
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Second, we used MDP as a natural and realistic approach to examine the optimal
timing of biologics in RA. Prior CEAs are limited because they reduce the complexity
of treatment sequences to a manageable set of treatment scenarios that are incapable
of capturing the optimal timing of biologics. For example, a standard decision tree
comparable to the MDP must evaluate 2 to the power of 500 treatment scenarios! Such
complexity is neither practical nor necessary. In the current study, we modeled the first
MDP to address the importance of the optimal timing of biologics.
We calculated different HAQ progressions for the first 3 years of RA (early RA) and
after the third year (established RA). We hypothesized that HAQ progression in early
RA may be more reflective of acute inflammatory disease and that would be different
than later on in the disease where HAQ progression may be more reflective of joint de-
formity with acute exacerbations. As we reduced the duration of early arthritis from 5
to 2 years, biologics appeared marginally more cost-effective in the early arthritis. This
finding supports the theory of a window of opportunity that biologics are marginally
more cost-effective. Due to sample limitations we were unable to estimate HAQ pro-
gressions for very early RA (i.e., first 3 months). Based on the results from a previous
CEA biologics were not cost-effective compared to nonbiologics in this period.[72] In
addition, two recent clinical trials also concluded comparable benefits of biologics and
nonbiologics in early arthritis.[100, 101]
Because we relied on observational data to estimate biologics and nonbiologics ef-
fectiveness, confounding was a potential limitation. Specifically, those who received
biologics in the NDB might have been at greater disability than those who received
nonbiologics. To address this issue, we restricted our analysis to those who were biolog-
ics nave when entered the DNB but eventually received biologics at some point during
their NDBs observation period. In addition, we estimated transitional probabilities
that adjust for the baseline HAQ scores for each 6-month period. Our analysis remains
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limited by other confounding variables that are not correlated with the base-line HAQ
score.
Our findings are in agreement with other published studies.[72, 42] Similar to our
analysis Finckh et al. found that biologics were not cost-effective at their full cost and
that biologics were marginally more cost-effective in early RA than established RA. Sim-
ilarly, Chen et al. found that using early RA data showed favorable results for biologics
compared to established RA. In Chens analysis, using biologics among patients with
established RA increased the incremental cost-effectiveness ratio of biologics compared
to nonbiologics by four-fold and well above acceptable WTP thresholds.
Timing of biologics and nonbiologics may impose a threat to the validity of our
results. By design, our analysis used data for patients who received biologics after
nonbiologics. As a result, in the data biologics were taken when the patients were older
and with higher number of comorbidities, both of which are shown to be associated with
higher HAQ scores. To address the potential impact of increased age and comorbidities
on HAQ progression, we conducted a separate analysis in which we used adjusted HAQ
scores by age and comorbidities in a multivariate regression analysis to define the health
states. These adjusted HAQ scores were highly correlated with the unadjusted scores
(correlation coefficient = 0.93) and the MDP results were robust to the adjusted scores.
An important limitation of the MDP is that past events cannot account for future
decisions. This is because the MDP computes the optimal decisions by simulating a
patients experience backwards in time starting at the end of life. As such, the MDP is
inherently incapable of capturing events that occur in the future. For example, we were
unable to incorporate drug discontinuations in our analysis. As a result, we assumed
that both biologics and nonbiologics can be continued indefinitely. For the same reason,
we were unable to incorporate the risk of adverse events (e.g., serious infection and
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malignancy) in the model. These adverse events are important consideration in bio-
logics recommendations. However, the evidence surrounding them is controversial. A
meta-analysis of clinical trials found 2 folds increase in the risk of serious infection and
3.3 folds increase in the risk of malignancy for biologics compared to placebo.[32] How-
ever, increased risks of serious infections and malignancy is not definite in observational
data.[94]
Finally, our analysis does not account for radiographic improvements. Two clinical
trial showed slower radiographic changes associated with receiving biologics compared
to nonbiologics.[100, 101] However these changes were very small in both trials and
significant in only one of them.[101] Even though we did not incorporate radiographical
changes in our model directly, these changes are found to be highly correlated with HAQ
scores especially over lengthier disease durations.[95]
4.5 Conclusion
Even though we found biologics not to be cost-effective as observed in real-life US
practices, we found strong indications that they are marginally more cost-effectiveness
in early versus established arthritis. Thus, a window of opportunity seems to exist in
early RA during which biologics are more beneficial in terms of improved health-related
quality of life and reduced productivity loss. However, biologics were only cost-effective
at significantly reduced prices.
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4.6 Tables
Table 4.1: The HAQ quintiles and associated health-related quality of life (QoL) weights,
direct and indirect costs, and RA specific mortality rates.
HAQ
QoL
Cost
Quintile Mean Ranges Direct Indirect
1 0.23 (0-0.375) 0.87 $349 $1113
2 0.7 (0.5-0.875) 0.81 $1044 $3331
3 1.13 (1-1.375) 0.74 $1702 $5427
4 1.52 (1.5-1.75) 0.67 $2275 $7253
5 2.02 (1.875-3) 0.57 $3026 $9649
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Table 4.2: Transition probabilities among HAQ quintiles by drug category and RA duration (early vs. established).
Nonbiologics Biologics
From\To
HAQ Quintile
Death
HAQ Quintile
Death
1 2 3 4 5 1 2 3 4 5
E
a
r
l
y
H
A
Q
Q
u
i
n
t
i
l
e
1 0.749 0.15 0.05 0.013 0.037 0.002 0.706 0.2 0.057 0.029 0.007 0.002
2 0.343 0.425 0.18 0.033 0.016 0.003 0.295 0.455 0.208 0.024 0.016 0.003
3 0.037 0.277 0.369 0.221 0.092 0.004 0.055 0.277 0.461 0.166 0.037 0.004
4 0.029 0.059 0.292 0.439 0.175 0.006 0.018 0.145 0.271 0.343 0.217 0.006
5 0.041 0.041 0.124 0.206 0.578 0.01 0.071 0.047 0.141 0.165 0.566 0.01
Death 0 0 0 0 0 1 0 0 0 0 0 1
E
s
t
a
b
l
i
s
h
e
d
H
A
Q
Q
u
i
n
t
i
l
e
1 0.688 0.135 0.028 0.008 0.008 0.134 0.682 0.14 0.029 0.008 0.008 0.134
2 0.145 0.446 0.172 0.028 0.006 0.204 0.152 0.423 0.187 0.027 0.009 0.204
3 0.018 0.12 0.408 0.124 0.032 0.298 0.022 0.14 0.386 0.127 0.027 0.298
4 0.005 0.016 0.12 0.335 0.12 0.404 0.006 0.021 0.144 0.303 0.122 0.404
5 0.003 0.003 0.013 0.049 0.357 0.575 0.005 0.005 0.021 0.073 0.321 0.575
Death 0 0 0 0 0 1 0 0 0 0 0 1
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Table 4.3: Optimal strategy by HAQ quintile, duration of RA and biologics costs.
Biologics Cost Duration
HAQ Quintiles
1 2 3 4 5
100% Early N N N N N
(Base-case) Late N N N N N
40%
Early N N B B B
Late N N N N B
25%
Early N N B B B
Late N N B B B
QALY only
Early B B B B B
Late N N B B B
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Table 4.4: Maximum net health benefit (NHB) by HAQ quintiles and biologics costs for
a newly diagnosed 45-year-old RA cohort.
Biologics Cost Outcome
HAQ Quintiles
1 2 3 4 5
100% NHB 10.08 9.86 9.38 9.06 8.76
(Base-case) QALYs 12.86 12.73 12.48 12.25 12.02
Costs 277,860 286,530 310,510 318,590 325,710
40%
NHB 10.31 10.11 9.68 9.35 9.05
QALYs 12.86 12.73 12.48 12.25 12.02
Costs 254,900 262,080 280,260 290,180 297,050
25%
NHB 10.57 10.37 9.99 9.66 9.37
QALYs 12.86 12.73 12.48 12.25 12.02
Costs 229,410 235,690 249,480 258,410 264,630
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Figure 4.1: Markov Decision Processes (MDP) outline.
HAQ Q1-HAQ Q5 corresond to the Health Assessment Questionnaire quintiles 1 through 5.
HAQ Q1
HAQ Q5
Death
HAQ Q1
Biologics
Nonbiologics
HAQ Q5
Death
Biologics
Nonbiologics
100 years99.5 years
HAQ Q1 HAQ Q1
Biologics
Nonbiologics
HAQ Q5
Death
HAQ Q5
Death
Biologics
Nonbiologics
45 years
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Figure 4.2: Proportions of the original RA cohort at each HAQ quintile and death for various ages.
Q1-Q5 correspond to quintiles of the Health Assessment Questionnaire 1 through 5.
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Chapter 5
Conclusion and Discussion
This thesis investigates various aspects of the cost-effectiveness of biologics in US clin-
ical practice settings. In Chapter 2, we developed a simulation model to conduct a
cost-effectiveness analysis (CEA) of biologics using clinical practice effectiveness data
from a large RA registry in the US (The National Data Bank for Rheumatic Diseases
[NDB]).[11] Based on real-life RA patient experiences, we simulated the long-term cost-
effectiveness of biologics compared to nonbiologics from a US societal perspective. We
were able to compare a large number of biologic sequences, take into account discon-
tinuation patterns of these drugs, and their potential adverse events. Using clinical
practice data as a source of model inputs, we found biologics strategies to be slightly
more effective and significantly more expensive than nonbiologics. As a result we found
the incremental cost-effectiveness ratio (ICER) of biologics compared to nonbiologics to
be very high.
Our results were in conflict with the findings from most RCT-based CEAs. Although
biologics may be cost-effective in RCT settings, most RA patients who receive biologics
are not eligible to participate in these RCTs [9], and biologics efficacy for RCT eligible
participants exceeds that of the ineligible participants [7]. Furthermore, RA treatment
guidelines are generally less strict in the US than other countries that have universal
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health insurance coverage and require strict adherence to guidelines for reimbursement
purposes. As a result, fewer patients who receive biologics in the US may meet the
RCT eligibility criteria. Consequently, the societal costs of biologics may far exceed
their benefits given willingness to pay thresholds often considered acceptable by many
healthcare agencies.
In Chapter 4, we attempted to reconcile the differences in the findings from our
effectiveness-based CEA with those based on RCTs. Specifically, we investigated whether
differences in the findings were due to the input parameter sources or from fundamental
structural differences among CEAs. We reviewed the literature for published CEAs of
biologics compared to nonbiologics, and developed a novel approach to meta-analyze
these studies on their input levels using the published sensitivity analysis results. We
investigated the implications of replacing RCT efficacy of biologics with effectiveness
from clinical practice on the results of previously published RCT-based CEAs. We
found that using clinical effectiveness can double the ICERs reported thus rendering
biologics twice less cost-effective.
We also found that CEAs sponsored by the pharmaceutical industry were more
likely to report favorable results than non-industry sponsored studies. These find-
ings confirmed the results of a prior analysis of the CEA Registry (available online at
http://tufts-nemc.org/cearegistry) which also found strong indications for publication
bias in CEAs.[12]
In addition to reconciling the differences between our approach and prior analyses,
this chapter also serves as the first meta-analysis effort specific to CEAs. Our approach
utilized the information provided in sensitivity analyses results and did not require access
the original models. This capability is of particular importance to policy and decision
makers because it provides important insight into various assumptions adopted in these
studies.[52, 13] Prior systematic reviews of CEAs have been limited to a descriptive
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analysis entailing mere comparison and contrasting of these studies, including a recent
systematic review of biologics CEAs in RA.[4] These systematic reviews were unable to
summarize the information provided in the original CEAs.
In Chapter 4, we adopted Markov decision prcesses (MDP) as a novel approach to
investigate the relative cost-effectiveness of biologics in early versus established RA. We
examined if there exists a window of opportunity during which biologics are most cost-
effective in RA. Although the concept of a window of opportunity for early diagnosis
and treatment is widely recognized among rheumatologists, it is unclear if during this
window biologics are also most cost-effective. Rheumatologists are often faced with the
decision of whether to start biologics in early arthritis or wait until the nonbiologics were
first tried and failed. In the base-case analysis, we found that (1) biologics were not cost-
effective at their full costs compared to WTP thresholds generally considered acceptable,
and (2) that biologics were marginally more cost-effective in early RA rather than later
in the course of the disease. These results directly address the cost considerations
involved in initiating biologics in early arthritis because guidelines recommend biologics
as second line agents after the cheaper nonbiologics were tried thus ignoring the potential
long-term benefits of these agents.
MDP is a natural choice for applications that investigate the optimal timing of a
decision. In this particular type of research questions, it is superior to traditional CEAs,
because it allows a large number of sequential decisions to be modeled efficiently. For
example, MDP has been successfully implemented in recommending the optimal timing
of liver transplantation and in treating chronic liver diseases and in the optimal timing
of HIV treatment strategies.[15, 14] Despite its clinical relevance, powerful properties,
and successful implementation, this tool remains underutilized in clinical settings.[98]
This thesis is the first application of MDP being used in identifying the optimal timing
to initiate biologics in rheumatoid arthritis.
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In summary, although biologics may be cost-effective in the strict RCT settings, we
found strong evidence that biologics are not utilized cost-effectively in clinical practice
in the US. The difference between our results and those from RCT-based CEAs can
be partially attributed to the input parameter estimates. Using parameter estimates
from the NDB nearly doubled the ICERs reported from RCT-based CEAs. In addition,
we found that at a reduced cost, biologics were marginally more cost-effective in early
rather than established RA.
Bibliography
[1] Bansback NJ, Regier DA, Ara R, et al. An overview of economic evaluations
for drugs used in rheumatoid arthritis: focus on tumour necrosis factor-alpha
antagonists. Drugs. 2005;65(4):473–96.
[2] Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of
Rheumatology recommendations for the use of disease-modifying antirheumatic
drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care
and Research. 2012;64(5):625–639.
[3] Smolen JS, Landewe´ R, Breedveld FC, et al. EULAR recommendations
for the management of rheumatoid arthritis with synthetic and biological
disease-modifying antirheumatic drugs. Annals of the Rheumatic Diseases.
2010;69(6):964–75.
[4] van der Velde G, Pham B, Machado M, et al. Cost-effectiveness of biologic re-
sponse modifiers compared to disease-modifying antirheumatic drugs for rheuma-
toid arthritis: a systematic review. Arthritis Care and Research. 2011;63(1):65–78.
[5] Wolfe F, Michaud K, Dewitt EM. Why results of clinical trials and observational
studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological
and interpretive issues. Annals of the Rheumatic Diseases. 2004;63 Suppl 2:ii13–
ii17.
69
70
[6] Kievit W, Adang EM, Fransen J, et al. The effectiveness and medication costs
of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid
arthritis from prospective clinical practice data. Annals of the Rheumatic Diseases.
2008;67(9):1229–34.
[7] Kievit W, Fransen J, Oerlemans A, et al. The efficacy of anti-TNF in rheumatoid
arthritis, a comparison between randomised controlled trials and clinical practice.
Annals of the Rheumatic Diseases. 2007;66(11):1473–8.
[8] Wolfe F, Michaud K, Pincus T. Do rheumatology cost-effectiveness analyses make
sense? Rheumatology. 2004;43(1):4–6.
[9] Vashisht P, Sayles H, Cannon GW, Kerr GS, Schwab P. Generalizability of pa-
tients with rheumatoid arthritis in biologic clinical trials. [Abstract]. Arthritis
and Rheumatism. 2011;63(Suppl):1200.
[10] Wolfe F, Michaud K. The Hawthorne effect, sponsored trials, and the over-
estimation of treatment effectiveness. The Journal of Rheumatology. 2010
Nov;37(11):2216–20.
[11] Wolfe F, Michaud K. A brief introduction to the National Data Bank for
Rheumatic Diseases. Clinical and Experimental Rheumatology. 2005;23(5 Suppl
39):S168–71.
[12] Bell CM, Urbach DR, Ray JG, et al. Bias in published cost effectiveness studies:
systematic review. BMJ. 2006;332:699–703.
[13] Pignone M, Saha S, Hoerger T. Challenges in systematic reviews of economic
analyses. Annals of Internal Medicine. 2005;142(12):1073–1080.
71
[14] Alagoz O, Maillart LM, Schaefer AJ, Roberts MS. The optimal timing of living-
donor liver transplantation. Management Science. 2004;50(10):1420–1430.
[15] Shechter SM, Bailey MD, Schaefer AJ, Roberts MS. The optimal time to initiate
HIV therapy under ordered health states. Operations Research. 2008;56(1):20–33.
[16] Cush JJ. Early rheumatoid arthritis - is there a window of opportunity? The
Journal of Rheumatology. 2007;80:1–7.
[17] Sesin Ca, Bingham CO. Remission in rheumatoid arthritis: wishful thinking or
clinical reality? Seminars in Arthritis and Rheumatism. 2005;35(3):185–96.
[18] Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the manage-
ment of early arthritis: report of a task force of the European Standing Committee
for International Clinical Studies Including Therapeutics (ESCISIT). Annals of
the Rheumatic Diseases. 2007;66(1):34–45.
[19] Kwoh, CK; Anderson, LG; Greene, JM; Johnson, DA; ODell, JR; Robbins M.
Guidelines for the management of rheumatoid arthritis: 2002 update Ameri-
can College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines.
Arthritis and Rheumatism. 2002;46(2):328–346.
[20] Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology
2008 recommendations for the use of nonbiologic and biologic disease-modifying
antirheumatic drugs in rheumatoid arthritis. Arthritis Care and Research.
2008;59(6):762–784.
[21] Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid
arthritis with a recombinant human tumor necrosis factor receptor (p75)fc fusion
protein. New England Journal of Medicine. 1997;337(3):141–147.
72
[22] van de Putte L, Rau R, Breedveld F, et al. Efficacy and safety of the fully human
anti-tumour necrosis factor monoclonal antibody adalimumab (D2E7) in DMARD
refractory patients with rheumatoid arthritis: a 12 week, phase II study. Annals
of the Rheumatic Diseases. 2003;62(12):1168–1177.
[23] Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-
tumor necrosis factor alpha monoclonal antibody, for the treatment of rheuma-
toid arthritis in patients taking concomitant methotrexate: the ARMADA trial.
Arthritis and Rheumatism. 2003;48(1):35–45.
[24] Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predic-
tors in patients with rheumatoid arthritis: a three-year study of 7,527 patients.
Arthritis and Rheumatism. 2003;48(10):2750–62.
[25] Ramey D, Raynauld J, Fries J. The health assessment questionnaire 1992. Status
and review. Arthritis and Rheumatism. 1992;5(3):119–129.
[26] Wolfe F, Michaud K, Gefeller O, Choi HK. Predicting mortality in patients with
rheumatoid arthritis. Arthritis and Rheumatism. 2003;48(6):1530–42.
[27] Brennan A, Bansback N, Reynolds A, Conway P. Modelling the cost-effectiveness
of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology.
2004;43(1):62–72.
[28] Wailoo AJ, Bansback N, Brennan A, Michaud K, Nixon RM, Wolfe F. Biologic
drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness anal-
ysis. Arthritis and Rheumatism. 2008;58(4):939–46.
[29] Michaud K, Wallenstein G, Wolfe F. Treatment and non-treatment predictors
of HAQ disability progression in RA: A longitudinal study of 18,485 patients.
Arthritis Care and Research. 2010;63(3):366 –372.
73
[30] Arias E. United States life tables, 2006. National vital statistics reports : from the
Centers for Disease Control and Prevention, National Center for Health Statistics,
National Vital Statistics System. 2010;58(21):1–40.
[31] Kuntz KM, Weinstein MC. Life expectancy biases in clinical decision modeling.
Medical Decision Making. 1995;15(2):158–69.
[32] Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-
TNF antibody therapy in rheumatoid arthritis and the risk of serious infections
and malignancies: systematic review and meta-analysis of rare harmful effects in
randomized controlled trials. JAMA. 2006;295(19):2275–85.
[33] Coyne P, Hamilton J, Heycock C, Saravanan V, Coulson E, Kelly CA. Acute
lower respiratory tract infections in patients with rheumatoid arthritis. Journal
of Rheumatology. 2007;34(9):1832–1836.
[34] Dombrovskiy VY, Martin Aa, Sunderram J, Paz HL. Rapid increase in hospital-
ization and mortality rates for severe sepsis in the United States: a trend analysis
from 1993 to 2003. Critical Care Medicine. 2007;35(5):1244–50.
[35] Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D. Cancer
risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of random-
ized controlled trials of adalimumab, etanercept, and infliximab using patient level
data. Pharmacoepidemiology and Drug Safety. 2011;20(2):119–30.
[36] Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of
malignancy: analyses from a large US observational study. Arthritis and Rheuma-
tism. 2007;56(9):2886–95.
74
[37] Coiffier B, Lepage E. CHOP chemotherapy plus rituximab compared with CHOP
alone in elderly patients with diffuse large-B-cell lymphoma. The New England
Journal of Medicine. 2002;346(4):235–242.
[38] Lee BY, Bailey RR, Smith KJ, et al. Universal Methicillin-Resistant Staphylo-
coccus Aureus (MRSA) surveillance for adults at hospital admission: an economic
model and analysis. Infection Control and Hospital Epidemiology. 2010;31(6):598–
606.
[39] Seidler AM, Bramlette TB, Washington CV, Szeto H, Chen SC. Mohs versus
traditional surgical excision for facial and auricular nonmelanoma skin cancer: an
analysis of cost-effectiveness. Dermatologic Surgery. 2009;35(11):1776–87.
[40] Hornberger JC, Best JH. Cost utility in the United States of rituximab plus
cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of
elderly patients with diffuse large B-cell lymphoma. Cancer. 2005;103(8):1644–51.
[41] Consumer Price Index Detailed Report, February 2010. Bureau of Labor Statis-
tics; 2010. Available from: http://www.bls.gov/cpi/cpid1002.pdf.
[42] Chen Yf, Jobanputra P, Barton P, et al. Adalimumab, etanercept and inflix-
imab for the treatment of rheumatoid arthritis. Health Technology Assessment.
2006;10(42):1–266.
[43] Stern R, Wolfe F. Infliximab dose and clinical status: results of 2 stud-
ies in 1642 patients with rheumatoid arthritis. The Journal of Rheumatology.
2004;31(8):1538–1545.
[44] Reuters T. Drug Topics Red Book 2009. 113th ed. Montvale, NJ: Thomson
Healthcare/Thomson PDR; 2010.
75
[45] Rogers HW, Coldiron BM. A relative value unit-based cost comparison of treat-
ment modalities for nonmelanoma skin cancer: effect of the loss of the Mohs
multiple surgery reduction exemption. Journal of the American Academy of Der-
matology. 2009;61(1):96–103.
[46] Kobelt G, Eberhardt K, Jo¨nsson L, Jo¨nsson B. Economic consequences of
the progression of rheumatoid arthritis in Sweden. Arthritis and Rheumatism.
1999;42(2):347–56.
[47] Choi HK, Seeger JD, Kuntz KM. A cost-effectiveness analysis of treatment op-
tions for patients with methotrexate-resistant rheumatoid arthritis. Arthritis and
Rheumatism. 2000;43(10):2316–27.
[48] Total coverage by ownership: Establishments, employment, and wages, 2000-2009
annual averages. Bureau of Labor Statistics; 2011. Available from: http://www.
bls.gov/cew/ew09table1.pdf.
[49] Healthcare Cost and Utilization Project (HCUP) 2007-2009. Rockville, MD.:
Agency for Healthcare Research and Quality; 2011. Available from: www.
hcup-us.ahrq.gov/nisoverview.
[50] Jobanputra P. A clinician’s critique of rheumatoid arthritis health economic mod-
els. Rheumatology. 2011;50 Suppl 4:iv48–iv52.
[51] Garattini L, Koleva D, Casadei G. Modeling in pharmacoeconomic studies: fund-
ing sources and outcomes. International journal of technology assessment in health
care. 2010 Jul;26(3):330–3.
[52] Mugford M. Using Systematic Reviews for Economic Evaluation. In: Systematic
Reviews in Health Care: Meta-Analysis in Context; 2001. .
76
[53] Jalal H, Dowd B, Sainfort F, Kuntz KM. Linear regression metamodeling as
a tool to summarize and present simulation model results. Medical Decision
Making. 2013;(June). Available from: http://www.ncbi.nlm.nih.gov/pubmed/
23811758.
[54] Diamantopoulos A, Benucci M, Capri S, et al. Economic evaluation of tocilizumab
combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy.
Journal of Medical Economics. 2012;15(3):576–85.
[55] Lindgren P, Geborek P, Kobelt G. Modeling the cost-effectiveness of treatment of
rheumatoid arthritis with rituximab using registry data from Southern Sweden.
International Journal of Technology Assessment in Health Care. 2009;25(2):181–9.
[56] Choi HK, Seeger JD, Kuntz KM. A cost effectiveness analysis of treatment op-
tions for methotrexate-naive rheumatoid arthritis. The Journal of Rheumatology.
2002;29(6):1156–65.
[57] Kobelt G. The cost-effectiveness of infliximab (Remicade) in the treatment of
rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT
study. Rheumatology. 2003;42(2):326–335.
[58] Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related
quality of life in rheumatoid arthritis: validity, responsiveness and reliability of
EuroQol (EQ-5D). British Journal of Rheumatology. 1997;36(5):551–9.
[59] Boggs R, Sengupta N, Ashraf T. Estimating health utility from a physical func-
tion assessment in rheumatoid arthritis (RA) patients treated with Adalimumab
(D2E7). Value in Health. 2002;5(6):452–453.
77
[60] Soini EJ, A HT, Puolakka K, Vihervaara V, Kauppi MJ. Cost-effectiveness of
adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-
severe rheumatoid arthritis. Journal of Medical Economics. 2012;15(2):340–351.
[61] Consumer Price Index - May 2013. Bureau of Labor Statistic; 2013. Report 202.
Available from: http://www.bls.gov/news.release/pdf/cpi.pdf.
[62] Schipper LG, Kievit W, den Broeder AA, et al. Treatment strategies aiming
at remission in early rheumatoid arthritis patients: starting with methotrexate
monotherapy is cost-effective. Rheumatology. 2011;50(7):1320–30.
[63] Farahani P, Levine M, Goeree R. A comparison between integrating clinical prac-
tice setting and randomized controlled trial setting into economic evaluation mod-
els of therapeutics. Journal of Evaluation in Clinical Practice. 2006;12(4):463–70.
[64] Marra CA, Marion SA, Guh DP, et al. Not all “quality-adjusted life years” are
equal. Journal of Clinical Epidemiology. 2007;60(6):616–24.
[65] Bansback NJ, Brennan A, Ghatnekar O. Cost effectiveness of adalimumab in the
treatment of patients with moderate to severe rheumatoid arthritis in Sweden.
Annals of the Rheumatic Diseases. 2005;64(7):995–1002.
[66] Barbieri M, Wong JB, Drummond M. The cost effectiveness of infliximab for
severe treatment-resistant rheumatoid arthritis in the UK. PharmacoEconomics.
2005;23(6):607–18.
[67] Barton P, Jobanputra P, Wilson J, Bryan S, Burls a. The use of modelling to
evaluate new drugs for patients with a chronic condition: the case of antibodies
against tumour necrosis factor in rheumatoid arthritis. Health technology assess-
ment. 2004;8(11):iii, 1–91.
78
[68] Benucci M, Gobbi FL, Sabadini L, Saviola G, Baiardp P, Manfredi M. The eco-
nomic burden of biological therapy in rheumatoid arthritis in clinical practice:
cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian.
International journal of immunopathology and pharmacology. 2009;22(4):1147–
1152.
[69] Brennan A, Kharroubi S. Calculating partial expected value of perfect information
via Monte Carlo sampling algorithms. Medical Decision Making. 2007;.
[70] Coyle D, Judd M, Blumenauer B, Cranney A, Maetzel A, Tugwell P WG. In-
fliximab and Etanercept in Patients with Rheumatoid Arthritis: A Systematic
Review and Economic Evaluation. Ottawa: Canadian Coordinating Office for
Health Technology Assessment; 2006. 64.
[71] Davies A, Cifaldi MA, Segurado OG, Weisman MH. Cost-effectiveness of sequen-
tial therapy with tumor necrosis factor antagonists in early rheumatoid arthritis.
The Journal of Rheumatology. 2009;36(1):16–26.
[72] Finckh A, Bansback N, Marra CA, et al. Treatment of very early rheumatoid
arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or
biologic agents. Annals of Internal Medicine. 2009;151(9):612.
[73] Jobanputra P, Research NHS, Programme DHTA, Assessment NCCHT. The ef-
fectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis:
a systematic review and economic evaluation. vol. 6. Core Research on behalf
of the National Coordinating Centre for Health Technology Assessment; 2002.
Available from: http://www.hta.ac.uk/pdfexecs/summ621.pdf.
[74] Kielhorn A, Porter D, Diamantopoulos A, Lewis G. UK cost-utility analysis of
rituximab in patients with rheumatoid arthritis that failed to respond adequately
79
to a biologic disease-modifying antirheumatic drug. Current Medical Research
and Opinion. 2008;24(9):2639–50.
[75] Kobelt G. TNF inhibitors in the treatment of rheumatoid arthritis in clinical
practice: costs and outcomes in a follow up study of patients with RA treated with
etanercept or infliximab in southern Sweden. Annals of the Rheumatic Diseases.
2004 Jan;63(1):4–10.
[76] Kobelt G, Lindgren P, Singh A, Klareskog L. Cost effectiveness of etanercept
(Enbrel) in combination with methotrexate in the treatment of active rheuma-
toid arthritis based on the TEMPO trial. Annals of the Rheumatic Diseases.
2005;64(8):1174–9.
[77] Kobelt G, Lekander I, Lang A, Raffeiner B, Botsios C, Geborek P. Cost-
effectiveness of etanercept treatment in early active rheumatoid arthritis followed
by dose adjustment. International Journal of Technology Assessment in Health
Care. 2011;27(3):193–200.
[78] Lekander I, Borgstro¨m F, Svarvar P, Ljung T, Carli C, van Vollenhoven RF. Cost-
effectiveness of real-world infliximab use in patients with rheumatoid arthritis
in Sweden. International journal of technology assessment in health care. 2010
Jan;26(1):54–61.
[79] Merkesdal S, Kirchhoff T, Wolka D, Ladinek G, Kielhorn A, Rubbert-Roth A.
Cost-effectiveness analysis of rituximab treatment in patients in Germany with
rheumatoid arthritis after etanercept-failure. The European Journal of Health
Economics. 2010;11(1):95–104.
80
[80] Spalding JR, Hay J. Cost effectiveness of tumour necrosis factor-alpha in-
hibitors as first-line agents in rheumatoid arthritis. PharmacoEconomics.
2006;24(12):1221–32.
[81] Tanno M, Nakamura I, Ito K, et al. Modeling and cost-effectiveness analysis of
etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis.
Modern Rheumatology. 2006;16(2):77–84.
[82] van den Hout WB, Goekoop-Ruiterman YPM, Allaart CF, et al. Cost-utility
analysis of treatment strategies in patients with recent-onset rheumatoid arthritis.
Arthritis and Rheumatism. 2009 Mar;61(3):291–9.
[83] Vera-Llonch M, Massarotti E, Wolfe F, et al. Cost-effectiveness of abatacept in
patients with moderately to severely active rheumatoid arthritis and inadequate
response to tumor necrosis factor-alpha antagonists. The Journal of Rheumatol-
ogy. 2008;35(9):1745–53.
[84] Virkki LM, Konttinen YT, Peltomaa R, et al. Cost-effectiveness of infliximab in
the treatment of rheumatoid arthritis in clinical practice. Clinical and experimen-
tal rheumatology;26(6):1059–66.
[85] Welsing PMJ, Severens JL, Hartman M, van Riel PLCM, Laan RFJM. Model-
ing the 5-year cost effectiveness of treatment strategies including tumor necrosis
factor-blocking agents and leflunomide for treating rheumatoid arthritis in the
Netherlands. Arthritis and Rheumatism. 2004 Dec;51(6):964–73.
[86] Wong J, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks
of infliximab for rheumatoid arthritis. The American Journal of Medicine.
2002;113:400–408.
81
[87] Yuan Y, Trivedi D, Maclean R, Rosenblatt L. Indirect cost-effectiveness analyses of
abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis
in the United States. Journal of Medical Economics. 2010;13(1):33–41.
[88] Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis.
Arthritis and Rheumatism. 1994;37(4):481–94.
[89] Zeidler H. The need to better classify and diagnose early and very early rheuma-
toid arthritis. The Journal of Rheumatology. 2012;39(2):212–7.
[90] Baumgartner S, Fleischmann RM, Moreland LW, Schiff MH, Markenson J, Whit-
more JB. Etanercept (Enbrel) in patients with rheumatoid arthritis with re-
cent onset versus established disease: improvement in disability. The Journal of
Rheumatology. 2004;31:1532–7.
[91] Neogi T, Aletaha D, Silman AJ, et al. The 2010 American College of Rheuma-
tology/European League Against Rheumatism classification criteria for rheuma-
toid arthritis: Phase 2 methodological report. Arthritis and Rheumatism.
2010;62:2582–91.
[92] Boers M. Cost-effectiveness of biologics as first-line treatment of rheumatoid
arthritis: case closed? Annals of Internal Medicine. 2009;151(9):668–669.
[93] Breedveld F. The value of early intervention in RA - a window of opportunity.
Clinical Rheumatology. 2011;30 Suppl 1:S33–9.
[94] Curtis JR, Singh JA. Use of biologics in rheumatoid arthritis: current and emerg-
ing paradigms of care. Clinical Therapeutics. 2011;33(6):679–707.
82
[95] Finckh A, Liang MH, van Herckenrode CM, de Pablo P. Long-term impact of early
treatment on radiographic progression in rheumatoid arthritis: A meta-analysis.
Arthritis and Rheumatism. 2006;55(6):864–72.
[96] Sokka T, Kautiainen H. Work disability in rheumatoid arthritis 10 years after the
diagnosis. The Journal of Rheumatology. 1999;26:1681–5.
[97] Sokka T, Pincus T. Eligibility of patients in routine care for major clinical trials
of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis and
Rheumatism. 2003;48(2):313–8.
[98] Alagoz O, Hsu H, Schaefer AJ, Roberts MS. Markov decision processes: a
tool for sequential decision making under uncertainty. Medical Decision Making.
2012;30(4):474–83.
[99] Stinnett A, Mullahy J. Net health benefits: a new framework for the analysis of
uncertainty in cost-effectiveness analysis. Medical Decision Making. 1998;18:S68–
80.
[100] O’Dell JR, Mikuls TR, Taylor TH, et al. Therapies for active rheumatoid arthritis
after methotrexate failure. New England Journal of Medicine. 2013 Jun;Available
from: http://www.nejm.org/doi/abs/10.1056/NEJMoa1303006.
[101] Moreland LW, O’Dell JR, Paulus HE, et al. A randomized comparative effec-
tiveness study of oral triple therapy versus etanercept plus methotrexate in early
aggressive rheumatoid arthritis: the Treatment of Early Aggressive Rheumatoid
Arthritis Trial. Arthritis and Rheumatism. 2012;64(9):2824–35.
[102] Schaefer AJ, Bailey MD, Shechter SM, Roberts MS. Modeling medical treatment
using Markov decision processes. Operations Research and Health Care. 2005;p.
593–612.
83
[103] Puterman ML. Markov Decision Processes: Discrete Stochastic Dynamic Pro-
gramming. Wiley; 2004.
[104] Bellman R. On the theory of dynamic programming. Proceedings of the National
Academy of Science; 1952.
Appendix A
Detailed Calculations of the Input Effect
Sizes (IES)
The following tables present the detailed calculation of the mean parameter and mean
input effect size (IES) for the six selected model parameters. These parameters are the
initial HAQ improvement, annual HAQ progression for biologics, annual background
HAQ progression, relative risk of mortality rate for each unit increase in HAQ, and the
RA-specific mortality rates. The ICERs are in currency per QALY. The currency type
and year vary from one study to another and is reported in Figure 3.2.
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Table A.1: Initial HAQ Improvement.
Author Year
Absolute Values Percentage Change
IESInput ICER Input ICER
Baseline V1 V2 Baseline V1 V2 V1 V2 V1 V2
Brennan 2004 -0.842 -0.662 -1.023 16372 19121 14507 -0.2139 0.2148 0.167 -0.1139 -0.657
Tanno 2006 -0.94 -0.752 -1.128 2.5 2.975 2.088 -0.2 0.2 0.19 -0.165 -0.887
Mean -0.891 -0.772
(S) -0.069 0.162
Notes: ICER = incremental cost-effectiveness ratio; V1 = first input value; V2 = second input value; IES = Input
effect size; S = standard deviation.
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Table A.2: HAQ/Utility Conversion Factor.
Author Year
Absolute Values Percentage Change
IESInput ICER Input ICER
Baseline V1 V2 Baseline V1 V2 V1 V2 V1 V2
Brennan 2004 -0.2 -1 -0.57
Bansback 2005 -0.28 -0.173 34030 35970 -0.382 0.057 -0.149
Davies 2008 -0.28 -0.17 46946 65172 -0.392 0.388 -0.988
Kielhorn 2008 -0.28 -0.173 14683 18872 -0.381 0.285 -0.747
Merkesdal 2010 -0.173 -0.28 15564 13535 0.616 -0.13 -0.211
Soini 2012 -0.32 -0.173 -0.188 19113 20893 20713 -0.458 -0.412 0.093 0.083 -0.202
Mean -0.255 -0.478
(S) -0.056 0.34
Notes: ICER = incremental cost-effectiveness ratio; V1 = first input value; V2 = second input value; IES = Input
effect size; S = standard deviation.
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Table A.3: HAQ progression while on biologics.
Author Year
Absolute Values Percentage Change
IESInput ICER Input ICER
Baseline V1 V2 Baseline V1 V2 V1 V2 V1 V2
Brennan 2004 0.015 0.034 16372 19933 1.266 0.217 0.171
Bansback 2005 0.034 0 34030 28230 -1 -0.17 0.17
Chen(TNF@1) 2006 0.03 0 200956 32447 -1 -0.838 0.838
Chen(TNF@3early) 2006 0.03 0 30812 19264 -1 -0.374 0.374
Chen(TNF@3Late) 2006 0.03 0 88319 32045 -1 -0.637 0.637
Chen(TNF@last) 2006 0.03 0 31056 22203 -1 -0.285 0.285
Davies 2008 0.044 0 46847 36010 -1 -0.231 0.231
Kielhorn 2008 0.017 0 14684 5013 -1 -0.658 0.658
Vera-Iloch 2008 0.015 0.031 45979 49708 1.066 0.081 0.076
Yuan 2010 0.015 0.031 51041 54523 1.066 0.068 0.063
Mean 0.026 0.351
(S) -0.01 0.27
Notes: ICER = incremental cost-effectiveness ratio; V1 = first input value; V2 = second input value; IES = Input
effect size; S = standard deviation.
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Table A.4: Background HAQ progression.
Author Year
Absolute Values Percentage Change
IESInput ICER Input ICER
Baseline V1 V2 Baseline V1 V2 V1 V2 V1 V2
Brennan 2004 0.13 0.065 16372 18661 -0.5 0.139 -0.279
Bansback 2005 0.132 0.107 34030 35320 -0.189 0.037 -0.2
Kobelt 2005 0.03 0 0.09 37331 38726 36779 -1 2 0.037 -0.014 -0.015
Chen(TNF@1) 2006 0.06 0.03 200956 206499 -0.5 0.027 -0.055
Chen(TNF@3early) 2006 0.06 0.03 30812 38334 -0.5 0.244 -0.488
Chen(TNF@last) 2006 0.06 0.03 31056 46659 -0.5 0.502 -1.004
Spalding 2006 -0.5 0.5 -0.035 -0.047 -0.012
Tanno 2006 2.5 2.548 2.481 -0.2 0.2 0.019 -0.007 -0.067
Kielhorn 2008 0.065 0.017 14684 34586 -0.738 1.355 -1.835
Lekander 2010 0.065 0.031 22780 35420 -0.523 0.554 -1.06
Mean 0.073 -0.501
(S) -0.034 0.61
Notes: ICER = incremental cost-effectiveness ratio; V1 = first input value; V2 = second input value; IES = Input
effect size; S = standard deviation.
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Table A.5: Mortality relative risk by HAQ.
Author Year
Absolute Values Percentage Change
IESInput ICER Input ICER
Baseline V1 V2 Baseline V1 V2 V1 V2 V1 V2
Wong 2002 1.77 30689 19400 -1 -0.367 0.367
Barbieri 2005 1.77 33618 26510 -1 -0.211 0.211
Brennan 2004 1.375 1 1.75 16372 20112 14428 -0.272 0.272 0.228 -0.118 -0.636
Chen(TNF@1) 2006 1.33 0 2.73 200956 461453 150735 -1 1.052 1.296 -0.249 -0.748
Chen(TNF@3early) 2006 1.33 0 2.73 30812 29304 31817 -1 1.052 -0.048 0.032 0.039
Chen(TNF@3Late) 2006 1.33 0 2.73 88320 66332 239798 -1 1.052 -0.248 1.715 0.962
Chen(TNF@last) 2006 1.33 0 2.73 31056 31056 29581 -1 1.052 0 -0.047 -0.023
Vera-Iloch 2008 1.8 1.5 2 45979 45748 45948 -0.166 0.111 -0.005 -0.001 0.016
Yuan 2010 1.8 1 2 51041 51748 51343 -0.444 0.111 0.013 0.005 -0.019
Soini 2012 1.33 1 19113 17818 -0.248 -0.067 0.273
Mean 1.516 0.044
(S) -0.231 0.48
Notes: ICER = incremental cost-effectiveness ratio; V1 = first input value; V2 = second input value; IES = Input
effect size; S = standard deviation.
90
Table A.6: RA specific mortality.
Author Year
Absolute Values Percentage Change
IESInput ICER Input ICER
Baseline V1 V2 Baseline V1 V2 V1 V2 V1 V2
Brennan 2004 2.975 1 5.975 16372 16129 16790 -0.663 1.008 -0.014 0.025 0.024
Bansback 2005 1.63 1 1.9 34030 29190 36940 -0.386 0.165 -0.142 0.085 0.404
Kobelt 2005 37331 36655 -1 -0.018 0.018
Merkesdal 2010 1.33 1 2 15564 12937 22580 -0.248 0.503 -0.168 0.45 0.834
Average 1.978 0.32
(S) -0.876 0.83
Notes: ICER = incremental cost-effectiveness ratio; V1 = first input value; V2 = second input value; IES = Input
effect size; S = standard deviation.
Appendix B
Early RA Treatment Guidelines
The following diagrams are reproduced from the 2008 American College of Rheumatol-
ogy (ACR) guidelines [20] for treating early cases of RA (duration < 3 months), and
the updated version [2] of these guidelines published in 2012. In the 2008 guidelines,
biologics are recommended in early RA if there is persistent disease activity despite
nonbiologics therapy and features of poor prognosis. Because of cost consideration, in
these guidelines, biologics are only recommended if there are no cost or insurance lim-
itations. The 2012 update of these guidelines is similar, but the decision point related
to biologics cost has been removed. Even though, biologics cost has is not directly ad-
dressed in the 2012 version, it still plays a key role in determining access to these drugs
and an important limiting factor of biologics prescription in early RA.
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Figure B.1: 2008 American College of Rheumatology (ACR) guidelins for treating early RA.
Reproduced from [20].
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Figure B.2: 2012 Update 2008 American College of Rheumatology (ACR) guidelins for treating early RA.
Reproduced from [2].
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Appendix C
Markov Decision Processes
This section provides a detailed description of Markov Decision Processes (MDP). MDP
originates from operational research. Since its conception, it has been successfully used
in many applications, including medical decision making. For example, Alagoz and
Schaefer provide a summary of several medical applications of MDP [98, 102]. Despite its
clinical relevance, powerful properties, and successful implementation, this tool remains
underutilized in medical decision making.[98]
The main advantage of MDP is the ability to model sequential decisions. Sequential
decisions are important in clinical practice since most medical decisions tend to recur
over time. It is theoretically possible to use standard decision models in these problems,
but exhausting all possible sequences requires a very large number of decision branches.
For example, in Chapter 4 if we tried to use a standard decision tree, we would have
needed more than 10500 decision branches which can easily overrun the capability of the
fastest computers. MDP is specifically designed to handle sequential decisions. Alagoz
et al illustrates the advantage of using MDP to setup a sequential decision problem
and the performace improvement gained with an MDP compared to a standard decision
tree.[98]
Standard textbooks such as Markov Decision Processes by Martin Puterman [103]
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are excellent resources for an in depth description of MDP. Although MDP and standard
Markov models are very similar in concept, their algorithms are fundamentally different.
While standard Markov decision trees use forward propagation in time, MDP utilizes a
technique referred to as the Backward Induction Algorithm by Bellman.[104]
Chapter 4, used a finite-horizon discrete-time MDP. Finite-horizon (vs. infinite-
horizon) indicates a limited duration because the model is limited by the patient’s
lifetime. Discrete-time (vs. continuous) indicates classification of time into a set of
distinct periods. While all MDP flavors share a similar setup, their algorithms are
somewhat different. We believe that the finite horizon discrete-time variety was the
most appropriate in our case. In this section, we provide further detail into the setup
and algorithm of this particular type of MDP. For further detail on the other types,
please refer to Puterman’s MDP textbook.[103]
C.1 MDP Setup
Figure C.1 illustrates the structure of a simple finite-horizon discrete-time MDP which
consists of five elements [103]:
• A set of decision epochs or time periods (T )
• A set of health states (S)
• A set of actions (A)
• A set of state and action dependent rewards (r)
• A set of state and action dependent transition probabilities (p)
At each decision epoch (t) all patients must reside in one of the health states (s). A
transitional probability (p) controls the flow of these patients among states over time.
This transitional probability is dependent on the health state (s), decision epoch (t) and
the action (a) chosen. A reward (r) accumulates as patients pass through the model.
In Chapter 4 we used net health benefits to measure reward, but rewards can be in
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the form of costs, or quality adjusted life years (QALYs), or any other type of relevant
rewards. These rewards are dependent on the state (s), time (t) and selected action (a).
This collection {T, S,As, pt(.|s, a), rt(s, a)} forms the structure of the Markov Decision
Process (MDP) [103].
Figure C.1 illustrates the setup of an MDP that consists of 3 decision epochs (t = 3),
3 health states (s = 3), and 4 actions (a = 4). Notice that no decision occurs in the last
period but it is still considered a decision epoch for mathematical convenience. Thus,
The number of decision epochs is always larger by one from the number of decisions
points. In this diagram, the transitional probabilities are represented by the arrows
pointing from the chance nodes to the health states in the next time period. Here we
assume that transitions among all states are possible following every actions except for s3
and a4. We also assume that s3 is an absorbing state (e.g. death) with arrows directing
to it from all other states. Once a patient enters this state they will stay there for the
rest of the simulation. These transitional probabilities are dependent on the originating
state, the transitioning state, and the action taken. As a result of transitioning from
one state to the next a reward (r) will accumulate. This reward is a function of both
residing in the health state and the chosen action. Table C.1 the standard mathematical
notation often used to describe MDP.
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Figure C.1: MDP Setup
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Table C.1: MDP Components
Parameter Values Description
T t ∈ T ; t = 1, ..., N A set of decision epochs (time periods)
S s ∈ S A set of mutually exclusive and collectively
exhaustible health states
As a ∈ As ⊆ A A set of actions available at state s. A repre-
sents the complete set of actions available for
all states. Actions can also depend on time t.
pt(.|s, a) p ∼ f(µ, σ) Transitional probability distribution at deci-
sion epoch t following action a, conditional
on being at state s
rt(s, a) Rewards Reward at state s at time t following action a
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Two key concepts in MDP that are decision rules (d) and policy (pi). Decision rules
are a set of rules that specify the relationship between actions, states and time. These
rules defined the relationship between various actions, states and decision epochs. It is
important to note that MDP is based on the ”Markovian” principle and is therefore is
memoryless. This means that the decision rule would be the same no matter the path
or history that led to being in a certain state at a certain time. Thus, prior actions and
states are irrelevant in MDP. That being said, modifications of the MDP exist that may
account for history. Readers see [103] for additional detail.
C.2 The Backward Induction Algorithm
Finite-horizon discrete-time MDP utilizes an algorithm referred to as the Backward
Induction Algorithm which finds the optimal policy (a sequence of decision rules) by
iterating through this set of Bellman equations [104]:
Step 1:
u∗N (si) = rN (si) (C.1)
Step 2, ..., N − 1:
u∗t (si) = max
a∈As
rt(si, a) + (1− α)∑
j∈S
pt(j|si, a)u∗t+1(j)
 (C.2)
where ∀si ∈ S, t = 1, ..., N − 1, u∗N (sN ) = health state specific maximum utility
at the last decision period representing the optimal choice for each health state at the
end of life, rN (sN ) = health state specific rewards at the last decision period (end of
life), u∗t (st) = health state specific maximum utility at decision periods before the last
period. Optimal choices at other years of life, α = discounting factor (e.g., 5%), u∗t+1
= state specific maximum utility and cumulative discounted future rewards at the next
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decision period, i = residing state, and j = transitioning state.
The objective of MDP is to find the optimal policy (pi∗). This is accomplished by
iterating from step 1 to N−1. At the end of these iterations, MDP finds the sequence of
actions (medications) that maximizes the cumulative stage and period specific rewards.
MDP identifies the optimal solution using the Backward Induction Algorithm. This
simply means starting the iterations from the end of the simulation instead of the
beginning. This is useful because there are no future rewards in the last period because
in this period, the optimal utility for each state u∗N (si) will simply be equal to the
state specific rewards rN (si) at the end of life. This last decision epoch will act as
the future rewards for all subsequent iterations. For example, the state specific reward
for periods N − 1 and N will be equal to the total of the state specific reward at
N − 1 summed with the discounted weighted average of future possible rewards (1 −
α)
∑
j∈S pt(j|si, a)u∗t+1(j). The weighted average of future rewards for a specific state
is equal to the sum of the products of transitional probability and the state specific
rewards at decision period N . At period N − 2, the total state specific rewards at
time N − 1 will become the future rewards. Equation (7) will recursively iterate until
it reaches the first decision period t = 1. Figures C.2, C.3 and C.4 present a visual
illustration of the MDP solution for this system of equations.
The shaded area represents the window that the MDP examines at each iteration.
In the first step (Figure C.2), this window is limited to the last decision period at
(t = N = 3). At this step no actions is chosen since the window does not cover any
decision nodes. The optimal utility for each of the states at this period is simply the
state specific reward at the last decision period (t3). For the subsequent iterations,
MDP extends the left margin of this shaded area until it stops when the last decision
period is covered (t = 1). For each of these iterations (t < N), the MDP recognizes
the state specific actions (a) that maximizes the rewards accumulated in this window.
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In each of these iterations, this area covers a new decision epoch. The system searches
this last covered epoch for the optimal action (a). The optimal action maximizes the
total of the state specific reward rt(s, a) and the discounted weighted average of future
rewards. Both the action (at) and maximum reward (u
∗
t ) will be recorded. After the
system finishes the final iteration, a series of decision epoch and state specific actions
(a∗t , t = 1, ..., N−1) will be identified. These sequences will be labeled the optimal policy
(δ∗). Figure 2 illustrates this solution for the simple example mentioned above. There
are no optimal actions for t3. Therefore, the optimal utility is simply the state specific
reward at time t3. This is illustrated by the shaded ares in Figure C.2. In step 2, the
state specific rewards obtained from step 1 will be weighted by the specific probabilities
and become the future rewards for t2. These future rewards are then discounted by a
factor (α). This will recur at the final step (step 3). The system finally stops when there
are no more decision nodes to cover. As a result of these iterations state specific policies
can be identified. For example for someone who starts at s2 at time t1, it is best to choose
a1. Choosing a1 most likely results in transitioning to s1 at t2. If this happens, then the
best action to take is to choose a2, as it result in transitioning to s2 at t3. This series of
decision rules guarantee the best cumulative reward. In summary, MDP is a powerful
tool for Markov problems that involve sequential decisions. However, this tool has been
inadequately explored by many modelers in MDM. This set of diagrams provides a
visual illustration of MDP that will facilitate the understanding and utilization of this
powerful tool in future MDM applications.
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Figure C.2: MDP Example: Step 1
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For each si ∈ S, i = 1, 2, 3, the optimal state specific utility u∗3si = r3(si)
For example, the reward of staying at state s2 represents the optimal utility for this
state.
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Figure C.3: MDP Example: Step 2
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For each si ∈ S, i = 1, 2, 3, u∗2(si) = maxa∈As
{
(r2(si, a) + (1− α)
∑
j∈S p2(j|si, a)u∗3(j)
}
For example, action a2 accumulates the maximum rewards for anyone residing in s1
at time t2. Action a2 will be chosen for state s1 at time t2.
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Figure C.4: MDP Example: Step 3
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For each si ∈ S, i = 1, 2, 3, u∗1(si) = maxa∈As
{
r1(si, a) + (1− α)
∑
j∈S p1(j|si, a)u∗2(j)
}
For example, action a1 will be chosen for s2 and time t1. Therefore, the best policy
for someone residing in s2 at time t1 is = a1 → a2 given the cohort passes through s1
at time t2.
Step 4: Stop the algorithm after reaching the first the last iteration (the first decision
epoch t = 1).
Appendix D
Defining Health States
The health states in Chapter 4 are defined by quintiles of HAQ. In this chapter we
present an alternative approach of defining the health states. This approach has two
advantages over the simple HAQ quintile classification. First, this approach controls
for time varying covariates, such as age, RA disease duration, and comorbidities. HAQ
scores are typically higher in older RA patients and those with longer RA duration
and higher number of comorbidities. At the same time, we in Chapter 4 we used
the period prior to biologics initiation to calculate the transition probabilities for the
nonbiologics while the period while on biologics as biologics transition. Thus, those who
receive biologics will typically be older, have lengthier disease duration and suffer more
comorbidities than those who received nonbiologics.
To control for time varying covariates we estimated a multi-variate regression anal-
ysis
HAQit = Ageit + Durationit + Comorbidiesit + eit
where i is the individual, t is time, and e is the residual term.
Figure D.1 illustrates the distribution of the unadjusted HAQ scores. This distribu-
tion is censored between 0 and 3, with a large peak at 0 indicating a large number of
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patient with minimal disability.
Figure D.1: HAQ Distribution
To account for this censoring, we used a Tobit model with upper and lower limits of
HAQ, such that
y∗i =

yi, if 0 < yi < 3
0, if yi ≤ 0
3, if yi ≥ 3
where y∗i is the latent HAQ score and yi is the observed HAQ score.
From this model the residual e represents the variation of HAQ unexplained by
age, duration or comorbidities, which is the variation we are interested in. Figure D.2
illustrates the distribution of e for biologics and nonbiologics.
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Figure D.2: Residuals by Biologics
e is normally distributed for both biologics and nonbiologics.
Next, we defined the health states as quintiles of e, and we estimated the mean HAQ
score within each quintile and how the RA patients are moving among these quintiles.
Figure D.3 illustrates the distribution of the HAQ scores among the residual quintiles.
It is also worth mentioning that the health states defined by quintiles of HAQ vs.
quintiles of the residuals were highly correlated (correlation coefficient = 0.93). In
addition, defining the health states with quintiles of the residual did not alter the results
of the Markov decision processes (MDP) (Chapter 4 )significantly. As a result we limited
the MDP analysis on the former classification of the health states based on the HAQ
quintiles.
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Figure D.3: Distribution of HAQ by residual Quintiles
Appendix E
Health-Related Quality of Life
This section presents the relationship between Health-Related Quality of Life (HR-
QoL) as measured by the EQ5D preference measurement and the Health Assessment
Questionnaire (HAQ) score. Both of these variables are observed in the NDB.
Figure E.1 illustrates the distribution of EQ5D (EuroQoL) by each HAQ category.
Figure E.1: Distribution of EuroQoL preference measures by HAQ
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It appears that the relationship between these two variables is more steep in the
higher categories of HAQ, i.e., the change in EQ5D corresponding to one unit increase
in HAQ is larger in the higher HAQ scores.
To further investigate this non-linearity we first regressed the EuroQoL on the first-
order HAQ score.
. regress euroqol haq
Source | SS df MS Number of obs = 117260
-------------+------------------------------ F( 1,117258) =95365.31
Model | 1746.11261 1 1746.11261 Prob > F = 0.0000
Residual | 2146.96175117258 .018309725 R-squared = 0.4485
-------------+------------------------------ Adj R-squared = 0.4485
Total | 3893.07436117259 .033200644 Root MSE = .13531
--------------------------------------------------------------------------------
euroqolus | Coef. Std. Err. t P>|t| [95% Conf. Interval]
---------------+----------------------------------------------------------------
HAQ | -.1679451 .0005438 -308.81 0.000 -.169011 -.1668792
Intercept | .9159529 .0006714 1364.18 0.000 .9146369 .9172689
--------------------------------------------------------------------------------
To examine the presence of non-linearity, we included a second term for HAQ2.
. regress euroqol haq haq2
Source | SS df MS Number of obs = 117260
-------------+------------------------------ F( 2,117257) =49396.76
Model | 1780.18791 2 890.093954 Prob > F = 0.0000
Residual | 2112.88645117257 .018019278 R-squared = 0.4573
-------------+------------------------------ Adj R-squared = 0.4573
Total | 3893.07436117259 .033200644 Root MSE = .13424
--------------------------------------------------------------------------------
euroqolus | Coef. Std. Err. t P>|t| [95% Conf. Interval]
---------------+----------------------------------------------------------------
HAQ | -.0977469 .001702 -57.43 0.000 -.1010828 -.0944109
HAQ2 | -.0320484 .000737 -43.49 0.000 -.0334928 -.0306039
Intercept | .8947341 .0008257 1083.63 0.000 .8931158 .8963525
--------------------------------------------------------------------------------
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Including the second order HAQ score increased the R2 from 0.449 to 0.457. Be-
cause this change was relatively small, we only included the first order HAQ score for
calculating the HR-QoL as a function of HAQ in this thesis.
